AP-4 vesicles unmasked by organellar proteomics

to reveal their cargo and machinery

Alexandra K. Davies¹, Daniel N. Itzhak², James R. Edgar¹, Tara L. Archuleta³,⁴, Jennifer Hirst¹,
Lauren P. Jackson³,⁴, Margaret S. Robinson¹*, Georg H. H. Borner²*

¹Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK
²Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry,
Martinsried 82152, Germany
³Department of Biological Sciences, Vanderbilt University, Nashville, TN 37235, USA
⁴Center for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA

*Correspondence: G.H.H.B., borner@biochem.mpg.de; M.S.R., msr12@cam.ac.uk
Abstract

Adaptor protein 4 (AP-4) is an ancient membrane trafficking complex, whose function has largely remained elusive. In humans, AP-4 deficiency causes a severe neurological disorder of unknown aetiology. We apply multiple unbiased proteomic methods, including ‘Dynamic Organellar Maps’, to find proteins whose subcellular localisation depends on AP-4. We identify three highly conserved transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3, and two AP-4 accessory proteins, RUSC1 and RUSC2. We demonstrate that AP-4 deficiency causes missorting of ATG9A in diverse cell types, including neuroblastoma and AP-4 patient-derived cells, as well as dysregulation of autophagy. Furthermore, we show that RUSC2 facilitates the microtubule plus-end-directed transport of AP-4-derived, ATG9A-positive vesicles from the TGN to the cell periphery. Since ATG9A has essential functions in neuronal homeostasis, our data not only uncover the ubiquitous function of the AP-4 pathway, but also begin to explain the molecular pathomechanism of AP-4 deficiency.
Introduction

Eukaryotic cells use a highly regulated system of vesicular and tubular transport intermediates to exchange molecules between organelles. Adaptor protein complex 4 (AP-4) is one of five related heterotetrameric AP complexes, which selectively incorporate transmembrane cargo proteins into nascent vesicles, and recruit machinery for vesicle budding and transport\(^1\). AP-4 consists of four subunits (\(\beta 4\), \(\epsilon\), \(\mu 4\), and \(\sigma 4\)) forming an obligate complex\(^2\text{--}^4\) (Fig. 1a). Loss-of-function mutations in any of the genes (\(AP4B1\), \(AP4E1\), \(AP4M1\), and \(AP4S1\)) cause a severe recessive neurological disorder with early-onset progressive spastic paraplegia and intellectual disability\(^5\text{--}^7\). AP-4-deficient patients have brain abnormalities including thinning of the corpus callosum\(^6,^8\text{--}^10\), indicating an important role for AP-4 in neuronal development and homeostasis. Axons of Purkinje and hippocampal neurons from \(Ap4b1\) knockout mice contain aberrantly accumulating autophagosomes that are immuno-positive for AMPA receptors\(^11\). However, the link between AP-4 deficiency and dysregulation of autophagy remains unclear.

While the clathrin adaptors AP-1 and AP-2 are well characterised, the function of AP-4, which does not associate with clathrin, has remained elusive. At steady state AP-4 localises to the trans-Golgi network (TGN)\(^2,^3\) and so is presumed to mediate cargo sorting at the TGN. The destination of the AP-4 trafficking pathway remains controversial, with conflicting reports suggesting transport to early endosomes\(^12,^13\), to late endosomes/lysosomes\(^14\) and, in polarised epithelial cells, to the basolateral membrane\(^15\). Likewise, AP-4 has been suggested to influence the sorting of various cargoes, including amyloid precursor protein\(^12,^13,^16\), low-density lipoprotein receptor\(^11,^15\), AMPA receptors\(^11\), and \(\delta 2\) glutamate receptors\(^11,^17\). However, several of these studies relied on exogenously
expressed proteins, while the potential endogenous cargoes (e.g. δ2 glutamate receptor) have cell-type-limited expression, unlike AP-4, which is ubiquitously expressed\textsuperscript{2,3}. There is currently no consensus which proteins are genuine cargoes of the AP-4 pathway, and hence no consensus as to its function. Similarly, AP-4 vesicle machinery is largely uncharacterised. The only identified AP-4 accessory protein is a cytosolic protein of unknown function called TEPSIN\textsuperscript{18}.

Due to the very low abundance of AP-4 (ca. 40-fold lower than AP-1 or AP-2 in HeLa cells\textsuperscript{19}), its functional characterisation has proved challenging. Nonetheless, given its ubiquitous expression in human tissues, AP-4 is likely to play a ubiquitous and important role in protein sorting, whose identification will be paramount to understanding AP-4 deficiency. Here, we combine orthogonal, unbiased and sensitive proteomic approaches to define the composition of AP-4 vesicles. From the intersection of our analyses we identify physiological cargo proteins of the AP-4 pathway, and novel AP-4 accessory proteins. We demonstrate that AP-4 is required for the correct sorting of three transmembrane cargo proteins, including ATG9A, which has essential functions in neuronal homeostasis. Thus, our data suggest a potential mechanistic explanation for the pathology caused by AP-4 deficiency.
Results

Dynamic Organellar Maps identify ATG9A, SERINC1 and SERINC3 as AP-4 cargo proteins

In AP-4-deficient cells, transmembrane cargo proteins that are usually transported in AP-4 vesicles, and cytosolic accessory proteins that are normally recruited by AP-4, are likely to be mislocalised. As an unbiased screen for such proteins, we used the ‘Dynamic Organellar Maps’ approach recently developed in our laboratory\textsuperscript{19,20}. This mass spectrometry (MS)-based method provides protein subcellular localisation information at the proteome level (Fig. 1b). A comparison of maps made from cells with genetic differences allows the detection of proteins with altered subcellular localisation.

We prepared maps from wild-type, \textit{AP4B1} knockout and \textit{AP4E1} knockout HeLa cells (Fig. 1c and Supplementary Fig. 1a, b), in biological duplicate (Fig. 1d and Supplementary Table 1). For every protein, we calculated the magnitude of localisation shifts between the wild-type and each knockout, and the reproducibility of the shift direction (Fig. 1e). Three proteins underwent significant and reproducible shifts in both knockout cell lines: SERINC1 and SERINC3 (Serine incorporator 1 and 3), multi-pass membrane proteins of unknown function, and ATG9A (Autophagy-related protein 9A; Fig. 1f). ATG9A is the only transmembrane core autophagy protein and is thought to play a key (though poorly defined) role in the initiation of autophagosome formation\textsuperscript{21}. The altered subcellular distribution of these proteins in AP-4-deficient cells identified them as candidate cargo proteins for the AP-4 pathway.

To begin to interpret the nature of the detected shifts, we used subcellular localisation information inferred from the maps. In both wild-type and AP-4 knockout cells,
ATG9A and SERINC family members were mapped to the endosomal cluster (Fig. 1g-i). However, this cluster comprises different types of endosomes, as well as the TGN\textsuperscript{19}. Scrutiny of the map visualisations (Fig. 1g-i) and marker protein neighbourhood analysis (Supplementary Table 2) suggested that in the knockouts both SERINC family members shifted intra-endosomally, while ATG9A localisation shifted from endosomes towards the TGN.

**Comparative vesicle proteomics identifies RUSC1 and RUSC2 as AP-4 accessory proteins**

Cytosolic proteins that only transiently associate with membrane may be missed by the Dynamic Organellar Maps approach, especially if they have low expression levels. We hence applied another proteomic approach developed in our lab, comparative vesicle profiling\textsuperscript{18}, to identify proteins lost from a vesicle-enriched fraction in the absence of AP-4 (Fig. 2a). This is particularly suited for identifying vesicle coat proteins. Cargo proteins are sometimes less strongly affected, as they may exist in several vesicle populations\textsuperscript{18}.

We used four different methods to ablate AP-4 function: (i) knockdown; (ii) knocksideways (a protein is rerouted to mitochondria, acutely depleting its cytosolic pool\textsuperscript{22}); (iii) knockout of AP4B1; (iv) knockout of AP4E1. Binary comparisons of AP-4-depleted and control vesicle fractions were performed by MS (Supplementary Fig. 2a and Supplementary Table 3) and principal component analysis was used to combine the information from all datasets (Fig. 2b). Proteins that were reproducibly lost from vesicle fractions from AP-4-depleted cells included the AP-4 subunits and TEPSIN, while SERINC1 and SERINC3 were the most depleted membrane proteins. ATG9A was affected to a lesser extent. Two related cytosolic proteins, RUSC1 and RUSC2 (RUN and SH3 domain-containing protein 1 and 2; Fig. 2c), were also reproducibly lost (Fig. 2b). They were not included in the maps since they are
barely detectable in subcellular membrane fractions. However, both proteins are highly enriched in the vesicle fraction, suggesting they are vesicle-associated proteins.

To investigate the RUSC-AP-4 relationship, we analysed total membrane fractions and whole cell lysates from control and AP-4 knockout cells by deep sequencing MS. RUSC2 (which has a lower whole cell copy number than RUSC1\(^1\)) was not consistently detected, but RUSC1 was dramatically lost from the total membrane fraction (>4-fold; Fig. 2d) and the whole cell lysate (>3-fold; Supplementary Fig. 1c) in knockout cells (Supplementary Table 4). This suggests that without AP-4, RUSC proteins are no longer recruited to the membrane, leading to their destabilisation. Mutations in RUSC2 have been reported in patients with phenotypes reminiscent of AP-4 deficiency\(^2\). Collectively, these data suggest that RUSC1 and RUSC2 are novel AP-4 accessory proteins.

**Proximity labelling and sensitive co-immunoprecipitation support that AP-4 interacts with ATG9A, SERINCs, and RUSC2**

AP complex-cargo interactions are transient and so have largely proved refractory to standard co-immunoprecipitation approaches. As an alternative we applied BioID, which uses a promiscuous biotin ligase, BirA*, to biotinylate proteins proximal to a protein of interest\(^3\). We stably expressed AP4E1-BirA* in HeLa cells and quantified biotinylated proteins by MS relative to controls (Fig. 2e and Supplementary Table 5). AP4E1-BirA* significantly biotinylated the other three AP-4 subunits and TEPSIN. ATG9A was the only significantly enriched transmembrane protein, consistent with it being an AP-4 cargo protein. SERINC1 and SERINC3 were not identified, likely due to low availability of lysine residues (the target of activated biotin) in their small cytosolic loops\(^4,5\). In addition, RUSC2
was significantly enriched, supporting its candidacy as an AP-4 accessory protein. Consistent results were obtained with AP4M1-BirA* (Supplementary Fig. 2b-d).

We next performed co-immunoprecipitation of the AP-4 complex via overexpressed TEPSIN-GFP, under sensitive low-detergent conditions (Fig. 2f and Supplementary Table 4). ATG9A, SERINC1 and SERINC3 were co-precipitated, confirming that they are cargo proteins of the AP-4 pathway. As expected, these interactions were not observable with a conventional immunoprecipitation protocol (Supplementary Fig. 2e).

Most AP complex accessory proteins interact with one or both C-terminal “ear” domains of the large subunits, including TEPSIN, which binds to the AP-4 β and ε appendage domains\textsuperscript{26,27}. As RUSC2 was identified by BioID, we tested whether GFP-RUSC2 would interact with either of the appendage domains in a GST pull-down experiment. GFP-RUSC2, but not GFP alone, was pulled down with both appendage domains, notably at higher levels with the ε ear (Fig. 2g), confirming that RUSC2 is a \textit{bona fide} AP-4 ear interaction partner.

In sum, using orthogonal proteomic approaches, we have identified three novel AP-4 cargo proteins, ATG9A, SERINC1 and SERINC3, and two novel AP-4 accessory proteins, RUSC1 and RUSC2. These are all low abundance proteins, expressed at comparable levels to AP-4 in HeLa cells\textsuperscript{19} (Fig. 2h) and primary mouse neurons\textsuperscript{20}.

**AP-4 is required for the correct subcellular localisation of ATG9A and SERINCS**

To further characterise the ATG9A and SERINC missorting phenotype we used immunofluorescence microscopy. In wild-type cells, ATG9A was detected as fine puncta with increased density in the juxtanuclear region (Fig. 3a), consistent with previous data\textsuperscript{28}. In contrast, there was a striking accumulation of ATG9A in the TGN region in both AP-4 knockout lines (Fig. 3a and Supplementary Fig. 3). Importantly, the mislocalisation of ATG9A
in the AP4B1 knockout was completely rescued by stable expression of the AP4B1 subunit (Fig. 3a). This was confirmed by quantitative automated imaging (Fig. 3b). To determine whether ATG9A is similarly affected by loss of AP-4 in a cell line more relevant to the neuronal phenotypes of AP-4 deficiency, we knocked out AP4B1 or AP4E1 in SH-SY5Y neuroblastoma cells (Fig. 3c). As before, loss of AP-4 caused a striking accumulation of ATG9A at the TGN (Fig. 3d).

Since there are no commercial antibodies that allow detection of endogenous SERINC1 or SERINC3, we used CRISPR to knock in fluorescent Clover tags at the endogenous loci (Supplementary Fig. 4a). Confocal microscopy with Airyscan enhanced resolution revealed the tagged SERINCs to localise to the perinuclear region and fine puncta throughout the cell (Fig. 4a, c). Strikingly, the peripheral SERINC-positive puncta showed considerable overlap with ATG9A, and AP-4 knockdown resulted in loss of these puncta, suggesting they were AP-4-derived vesicles (Fig. 4a-d and Supplementary Fig. 4b). In the AP-4-depleted cells, the SERINCs accumulated in the perinuclear area, although unlike ATG9A, they displayed little colocalisation with TGN46 (Supplementary Fig. 4c, d).

**AP-4-derived vesicles accumulate at the cell periphery in RUSC2-overexpressing cells**

We created HeLa cell lines that stably overexpress GFP-tagged RUSC2 and found it to localise to fine puncta throughout the cell, with a concentration in clusters at the periphery (Fig. 5a and Supplementary Fig. 5a). Overexpression of RUSC2 resulted in a dramatic relocation of ATG9A and SERINCs to the cell periphery, where they colocalised with the GFP-tagged RUSC2 (Fig. 5a, b and Supplementary Fig. 5a, b). This effect was specific for AP-4.
cargo proteins; other membrane proteins and organellar markers did not respond to
overexpression of RUSC2 (Supplementary Fig. 5c).

The localisation of AP-4 itself was not affected by RUSC2 overexpression
(Supplementary Fig. 6a), but we hypothesised that the peripheral structures in RUSC2-
overexpressing cells might be AP-4-derived vesicles. Consistent with this, GFP-RUSC2
expressed in AP-4 knockout and knockdown cells neither accumulated at the cell periphery,
nor colocalised with ATG9A (Fig. 6a and Supplementary Fig. 6b, c). Importantly, both the
peripheral distribution of GFP-RUSC2 and its colocalisation with ATG9A were restored in the
AP4B1 knockout by transient expression of the missing AP-4 subunit (Fig. 6a). This
demonstrates that the peripheral RUSC2/ATG9A/SERINC-positive structures are AP-4-
dependent compartments. The absence of AP-4 from the accumulating structures suggests
that it is released soon after budding, as is typical of most known vesicle coats.

Given the colocalisation between RUSC2 and ATG9A, we tested whether ATG9A and
GFP-RUSC2 interact physically. ATG9A co-precipitated with GFP-RUSC2 from wild-type but
not AP4B1 knockout cells (Fig. 6b). This demonstrates that the interaction between RUSC2
and ATG9A (which could be indirect) requires AP-4, suggesting that the three proteins come
together transiently during the formation of AP-4 vesicles.

Ultrastructural analysis by correlative light and electron microscopy (CLEM) revealed
that the peripheral clusters of GFP-RUSC2-positive puncta corresponded to an accumulation
of uncoated vesicular and tubular structures (Fig. 6c). Their peripheral localisation suggested
targeting to the plus-ends of microtubules, and RUSCs have been implicated in microtubule-
based transport. Treatment with nocodazole prevented the peripheral localisation of GFP-
RUSC2 but, unlike in AP-4-deficient cells, GFP-RUSC2 still co-localised with ATG9A (Fig. 6d).
These data suggest that the distribution of AP-4 vesicles requires microtubule-based transport, whereas their formation does not.

**AP-4 deficiency causes dysregulation of autophagy in HeLa cells**

*Ap4b1* knockout mice show aberrant accumulation of autophagosomes in neuronal axons, and increased levels of the autophagic marker protein LC3B\(^1\). We investigated if there were similar effects on autophagy in our AP-4 knockout HeLa cells. Wild-type and *AP4E1* knockout cells were grown in complete or starvation medium (to induce autophagy), with or without bafilomycin A1 (which blocks autophagosome degradation). The level of LC3B was then assessed by Western blotting (Fig. 7a). In untreated cells, there were increased levels of unlipidated LC3B-I and lipidated LC3B-II in the *AP4E1* knockout. Under starvation conditions (when LC3B-I is mostly converted into LC3B-II), there was also increased LC3B-II in the *AP4E1* knockout, which increased further in the presence of bafilomycin A1. This suggests that the elevated level of LC3B-II was not due to a block in degradation. Comparison of the relative amounts of LC3B-II with and without bafilomycin A1 in the wild-type versus the AP-4 knockout cells also suggested comparable levels of autophagic flux. The same trends were seen when comparing *AP4B1* knockout cells with the AP4B1 rescued cell line (Fig. 7b). Quantitative MS confirmed the increased level of total LC3B in whole cell lysates of untreated AP-4 knockout cells (median 1.5-fold increase; Supplementary Fig. 1c and Supplementary Table 4).

Elevated LC3B-II may reflect an increase in autophagosome size\(^3\). To test this, we visualised LC3B-positive structures by immunofluorescence microscopy in wild-type, *AP4B1* knockout, and AP4B1 rescued cells, following two hours starvation (Fig. 7c). Quantification through automated imaging showed an increase in the size of LC3B puncta in the knockout

*Davies et al., 2017*
cells (Fig. 7d), but no significant change in the number of puncta (Supplementary Fig. 7a). Larger LC3B puncta were also observed in AP4E1 knockout cells (Supplementary Fig. 7b). Collectively, these data suggest that lack of AP-4 in HeLa cells causes dysregulation of autophagy.

**ATG9A mislocalisation is a ubiquitous phenotype in cells from AP-4 deficient patients**

We analysed fibroblasts from patients with homozygous mutations in one of the AP-4 genes\(^5,6,31,32\) by immunofluorescence microscopy (Fig. 8a). Mutations in any of the four subunits caused a striking accumulation of ATG9A at the TGN. In addition, fibroblasts from an individual with a heterozygous loss-of-function mutation in AP4E1 (the phenotypically normal mother of the homozygous AP4E1 patient) displayed normal ATG9A localisation, so mislocalisation of ATG9A is a cellular phenotype that correlates with disease in AP-4 deficiency.

The microscopy indicated that there was also an increase in the overall ATG9A signal in the patient cells. Western blotting confirmed a large increase in the amount of ATG9A in whole cell lysates from all four patient cell lines and an intermediate level in the unaffected AP4E1 heterozygote (Fig. 8b). These data suggest that AP-4-deficient cells compensate for the missorting of ATG9A by increasing its expression, further supporting the importance of AP-4 in the regulation of ATG9A trafficking.
Discussion

The nature of AP-4 vesicles and their role in membrane trafficking has remained elusive for the two decades since their discovery. Here we have used orthogonal global proteomic tools to delineate the function of the AP-4 pathway. We identified three transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3, and two novel AP-4 accessory proteins, RUSC1 and RUSC2. Our approach was hypothesis-free and analysed the subcellular distribution of endogenous proteins. The latter is critical for assessing the role of trafficking pathways, especially for AP-4, which is of comparatively low abundance. When we overexpressed our AP-4 cargo proteins, they were no longer trafficked in an AP-4-dependent manner (data not shown), suggesting that investigations based on overexpressed candidate cargo proteins are likely to lead to spurious results. The AP-4-associated proteins identified in this study all have low expression levels similar to those of AP-4 itself\(^{19}\), highlighting the sensitivity of our approach. They are also, like AP-4, expressed ubiquitously. ATG9A localisation depends on AP-4 not only in HeLa cells, but also in neuroblastoma-derived SH-SY5Y cells and in fibroblasts from AP-4-deficient patients (Fig. 3 and Fig. 8a), suggesting that trafficking of ATG9A from the TGN is a ubiquitous function of AP-4.

Our data strongly support a model whereby AP-4 packages ATG9A, SERINC1 and SERINC3 into vesicles at the TGN, which associate via the RUSCs with machinery for microtubule plus-end-directed transport to the cell periphery (Fig. 8c). Neuronal deficiency of Atg9a in mice leads to progressive axonal degeneration, ataxia and convulsions\(^{33}\). Thus, provided that AP-4 has equivalent functions in neurons and HeLa cells, which our neuroblastoma data support (Fig. 3d), a hypothesis for neuronal AP-4 pathology emerges.
Neurons require efficient long-range transport, especially towards the distal axon, rendering them susceptible to disturbances in membrane trafficking\textsuperscript{34}. Furthermore, microtubules are unipolar in axons, with distally localised plus-ends\textsuperscript{35}, and it has been shown in \textit{Caenorhabditis elegans} that Atg9-containing vesicles are transported towards the distal axonal microtubule plus-ends\textsuperscript{36}. The distal axon is also an important site of autophagosome biogenesis\textsuperscript{37,38}. Our model suggests that in neurons lacking AP-4, ATG9A will not be packaged correctly at the TGN, and will not efficiently reach the distal axon. This may interfere with the spatial regulation of autophagy and/or with other functions of ATG9A, disrupting neuronal homeostasis.

The identification of ATG9A as an AP-4 cargo may also explain the aberrant accumulation of autophagosomes in neuronal axons of \textit{Ap4b1} knockout mice\textsuperscript{11}. There is a similar dysregulation of autophagy in AP-4 knockout HeLa cells, which contain enlarged autophagosomes and increased levels of LC3B (Fig. 7). Basal elevation of LC3B-I and LC3B-II has been observed in \textit{ATG9A} knockout HeLa cell lines\textsuperscript{39–41}, so our data are consistent with ATG9A mistrafficking leading to impaired ATG9A function. The role of ATG9A in autophagy is poorly defined, but it is thought to act early in autophagosome biogenesis without becoming incorporated into autophagosome membrane itself\textsuperscript{21}. In yeast the phagophore assembly site originates from Atg9-positive clusters of vesicles and tubules (the “Atg9 reservoir”)\textsuperscript{42}. Likewise, in mammalian cells Atg9 localises to a tubulovesicular compartment, distinct from other organellar markers\textsuperscript{21}. The AP-4-derived ATG9A-positive vesicles and tubules we have observed at the periphery of RUSC2-overexpressing cells fit the description of this compartment (Fig. 6c). In AP-4-deficient cells, ATG9A trafficking may be stalled at the TGN and the peripheral “ATG9A reservoir” depleted. Further investigation is necessary to understand how this may lead to the observed effects on autophagosomes in AP-4-deficient
cells. ATG9A mistrafficking has been linked previously to an accumulation of enlarged immature autophagosomes in Niemann-Pick type A patient fibroblasts\textsuperscript{43}. However, ATG9A has functions independent of autophagy\textsuperscript{33,44,45}, which may also be relevant to potential pathogenic effects caused by its missorting.

Loss-of-function mutations in RUSC2 cause a neurological disorder with considerable overlap with the AP-4 deficiency phenotype\textsuperscript{23}. This is in keeping with our identification of RUSCs as AP-4 accessory proteins. It will be interesting to look for similar ATG9A and SERINC sorting defects in cells from RUSC2-deficient patients. The RUSCs are poorly characterised but implicated in vesicular transport\textsuperscript{29,46}. RUSC1 has been proposed to act as a vesicle-transport adaptor by linking syntaxin-1 to kinesin-1 motors\textsuperscript{29}. Our data suggest that RUSC2 may similarly link AP-4 vesicles to microtubule transport machinery (Fig. 6).

The presence of SERINC1 and SERINC3 in the ATG9A tubulovesicular compartment warrants further investigation. Little is known about the function of SERINCs, despite their recent identification as HIV restriction factors\textsuperscript{47–49} and their high degree of conservation in all branches of eukaryotes. They were originally proposed to mediate the incorporation of serine into membrane lipids\textsuperscript{50}, but recent functional studies have shown no effect on membrane composition\textsuperscript{51,52}. Our discovery that ATG9A and SERINCs are trafficked together suggests a functional relationship.

In conclusion, this study has greatly expanded our understanding of the AP-4 pathway. The identification of novel AP-4 cargo and accessory proteins provides tools for further investigation of AP-4 function, generates hypotheses about the pathomechanism of AP-4 deficiency, and marks a significant step towards the development of possible treatments.
Methods

Antibodies

The following antibodies were used in this study: mouse anti-alpha tubulin 1:10,000 for WB (DM1A, T9026, Sigma-Aldrich), rabbit anti-AP4B1 1:400 for WB, rabbit anti-AP4E1 1:1000 for WB (both in-house\(^3\)), mouse anti-AP4E1 1:100 for IF (612019; BD Transduction Labs), rabbit anti-ATG9A 1:1000 for WB and 1:100 for IF (ab108338, Abcam), mouse anti-CIMPR 1:200 for IF (ab2733, Abcam), rabbit anti-clathrin heavy chain 1:10,000 for WB (in-house\(^3\)), mouse anti-EEA1 1:500 for IF (610457, BD Transduction Labs), rabbit anti-GFP 1:500 for IF (gift from Matthew Seaman, University of Cambridge), rabbit anti-GFP 1:1000 for WB (ab6556, Abcam), chicken anti-GFP 1:500 for IF (ab13970, Abcam), mouse anti-HA (16B12, Covance), mouse anti-LAMP1 1:100 for IF (H4A3), rabbit anti-LC3B 1:2000 for WB (L7543, Sigma-Aldrich), mouse anti-LC3B 1:400 for IF (M152-3, MBL International), rabbit anti-TEPSIN 1:1000 for WB and 1:250 for IF (in-house\(^3\)), and sheep anti-TGN46 1:200 for IF (AHP500, Bio-Rad). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Sigma-Aldrich (1:10,000). Fluorescently labelled secondary antibodies used in this study were Alexa488-labelled goat anti-chicken IgY (A11039), Alexa488-labelled donkey anti-mouse IgG (A21202), Alexa555-labelled donkey anti-mouse IgG (A31570), Alexa594-labelled donkey anti-mouse IgG (A21203), Alexa488-labelled donkey anti-rabbit IgG (A21206), Alexa555-labelled goat anti-rabbit IgG (A21429), Alexa594-labelled donkey anti-rabbit IgG (A21207), Alexa647-labelled donkey anti-rabbit IgG (A31573), Alexa488-labelled donkey anti-sheep IgG (A11015), Alexa594-labelled donkey anti-sheep IgG (A11016), and Alexa680-labelled donkey anti-sheep IgG (A21102), all purchased from Invitrogen and used at 1:500.
Constructs

A modified retroviral pLXIN vector (pLXINmod) was a gift from Andrew Peden (University of Sheffield). Myc-BirA* cDNA was amplified from pcDNA3.1_mycBioID (a gift from Kyle Roux; Addgene plasmid #35700[^24]) by PCR. AP4B1 cDNA was amplified from a full-length IMAGE clone (2906087), AP4E1 cDNA from a full-length IMAGE clone (40146497), and AP4M1 and AP4S1 cDNAs from sequence verified EST clones. The control BioID construct, pEGFP-myc-BirA*, was made by cloning myc-BirA* cDNA into a pEGFP-N2 vector (Clontech) using BsrGI and XbaI restriction sites. The AP4E1 BioID construct was made using Gibson Assembly Master Mix (E2611, New England BioLabs) to introduce myc-BirA* into the flexible hinge region of AP4E1, between residues 730 and 731, inserted into the pLXINmod vector linearised with an Hpal restriction site. For AP4B1, AP4M1 and AP4S1 BioID constructs, a C-terminal myc-BirA* tagging construct was used. This was generated using Gibson Assembly to introduce myc-BirA*, preceded by a glycine-serine linker (10 amino acids) and an upstream BgIII site, into the Hpal site of pLXINmod. The BgIII site was used to linearise the myc-BirA* tagging construct and cDNAs for AP4B1/M1/S1 were added by Gibson Assembly. RUSC2 cDNA was amplified from pCMV-SPORT6_RUSC2 (MHS6278-202800194, Thermo Fisher Scientific) and GFP cDNA was amplified from pEGFP-N2. Constructs for stable overexpression of GFP-tagged RUSC2, pQCXIH_GFP-RUSC2 and pQCXIH_RUSC2-GFP, were generated using Gibson Assembly to introduce RUSC2 and GFP cDNAs into the retroviral vector pQCXIH (Clontech). The AgeI site of pQCXIH was used for GFP-RUSC2 and the NotI site for RUSC2-GFP. pQCXIH_HA-RUSC2 was made by cutting out GFP from pQCXIH_GFP-RUSC2 with NotI and AgeI restriction sites and replacing it with a triple HA tag. SERINC3 cDNA was amplified from pSERINC3-mCherry, a custom synthetic construct (Genecust) based on the SERINC3 clone AAD22448.1, with several silent nucleotide substitutions.

[^24]: Davies et al., 2017
construct for stable overexpression of HA-tagged SERINC3, pLXIN\_SERINC3\_HA, was made using Gibson Assembly to introduce an HA tag between residues 311 and 312 of SERINC3 (within an extracellular loop), inserted into the pLXINmod vector linearised with HpaI. For generation of the AP-4 knocksideways construct, a sequence encoding the FKBP domain preceded by a short linker sequence (GALVNGGPEPAKNLYT) was cloned into the natural Sac1 site of the AP4E1 cDNA in vector pLXINmod, to introduce FKBP into the flexible hinge region of AP4E1 between residues 730 and 731. The sequences of all constructs described here were verified by Sanger DNA sequencing.

**Cell culture**

HeLa M cells and HEK 293ET cells were gifts from Paul Lehner (University of Cambridge). The human neuroblastoma cell line SH-SY5Y was a gift from Geoff Woods (University of Cambridge). The HeLa cells stably expressing BirA* were a gift from Folma Buss (University of Cambridge) and the HeLa cells stably expressing EGFP were a gift from Matthew Seaman (University of Cambridge). The HeLa cells stably expressing TEPSIN-GFP used for the conventional immunoprecipitation were previously described\(^\text{18}\). The AP4B1 knockout HeLa cells (clone x2A3), wild-type β4 rescued AP4B1 knockout HeLa cells, and HeLa cells stably expressing TEPSIN-GFP used for the sensitive immunoprecipitation were previously described\(^\text{26}\). The human fibroblasts from AP-4 deficient patients have been previously described and reduced AP-4 complex formation has been demonstrated for all patient lines. Molecular details of mutations and references for each are as follows: AP4B1*, GenBank NM\_006594: c.487\_488insTAT, p.Glu163_Ser739delinsVal\(^\text{5,18}\); AP4E1*, GenBank NM\_007347: c.3313C>T, p.Arg1105*\(^\text{31}\); AP4M1*, GenBank NM\_004722: c.1137+1G>T, p.Ser342ArgfsTer65\(^\text{6,18}\); AP4S1*, GenBank NM\_007077: c.[289C>T];[138+3_6delAAGT],

Davies et al., 2017
p.[Arg97*];[?]32 (the second mutation, which is at a splice donor site, was originally inaccurately reported as c.138_140delAATG). The control fibroblasts (from a healthy control donor) were a gift from Craig Blackstone (NIH) and the heterozygous AP4E1WT/AP4E1* fibroblasts were from the unaffected mother of the homozygous AP4E1* patient.

HeLa M cells were maintained in RPMI 1640 (R0883, Sigma-Aldrich). SH-SY5Y cells and human fibroblasts were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (D6546, Sigma-Aldrich). All media was supplemented with 10% v/v foetal calf serum, 4 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin and all cells were cultured at 37°C under 5% CO2. Stable cell lines were additionally maintained with 500 µg/mL G418 or 150 µg/mL hygromycin as appropriate. For metabolic labelling, HeLa cells were cultured in SILAC RPMI 1640 medium (89984, Thermo Fisher Scientific), supplemented with 10% (v/v) dialysed foetal calf serum (10,000 MW cut-off; Invitrogen), penicillin, streptomycin, and either “Heavy” amino acids (L-arginine-13C615N4:HCl (50 mg/L) and L-lysine-13C615N2:2HCl (100 mg/L); Cambridge Isotope Laboratories), or the equivalent “Light” amino acids55. Cells were cultured for at least seven days in these media before experiments were performed. For the “Dynamic Organellar Maps”, TEPSIN-GFP immunoprecipitations, membrane fraction and whole cell lysate analyses, SILAC labelling was performed as previously described19.

Transient DNA transfections were carried out using a TransIT-HeLaMONSTER® kit (Mirus Bio LLC), according to the manufacturer’s instructions. Stable cell lines were created using retrovirus made in HEK 293ET cells transfected using TransIT-293 Transfection Reagent (Mirus Bio LLC), according to the manufacturer’s instructions. pLXIN or pQCXIH plasmids were mixed with the packaging plasmids pMD.GagPol and pMD.VSVG in a ratio of 10:7:3. Viral supernatants were harvested after 48 hours, filtered through a 0.45 µm filter,

Davies et al., 2017
supplemented with 10 µg/mL hexadimethrine bromide (Polybrene, Sigma-Aldrich) and applied directly to the target cells at 37°C. Antibiotic selection for stable expression (500 µg/mL G418 or 150 µg/mL hygromycin) was initiated 48 hours post-transduction. When necessary due to variable levels of transgene expression in mixed populations of stably transduced cells, cell lines were single cell cloned by serial dilution. For generation of the AP-4 knocksideways cell line, the AP4E1-FKBP construct was introduced into HeLa cells stably expressing a mitochondrially targeted bait (YFP-FRB), as described\textsuperscript{22}. Clonal cell lines were isolated, and selected for appropriate expression levels. Correct localisation of the AP4E1-FKBP and rapamycin-induced rerouting of AP-4 to mitochondria were verified by microscopy (unpublished observations).

Knockdown of AP-4 was achieved by combined siRNA targeting of AP4E1 and AP4M1 using ON-TARGETplus SMARTpools (AP4E1, L-021474-00; AP4M1, L-011918-01; Dhharmacon), using a double-hit 96 hours protocol\textsuperscript{18}. For the first hit the final concentration of siRNA was 40 nM (20 nM AP4M1 + 20 nM AP4E1). The second hit was performed 48 hours after the first hit with half the final concentration of siRNA. Transfections of siRNA were carried out with Oligofectamine (Thermo Fisher Scientific), according to the manufacturer’s instructions and where indicated cells were mock treated with Oligofectamine without siRNA. For AP-4 knocksideways, cells were treated with rapamycin at 200 ng/mL final concentration (from a 1 mg/mL stock in ethanol) for 60 minutes, as described\textsuperscript{22}.

Where indicated cells were treated with 10 µg/mL nocodazole in cell culture medium for 2 hours at 37°C. For starvation during autophagy assays, cells were washed 3 times with Earle’s balanced salt solution (EBSS) and incubated in EBSS for the specified time. Where
indicated cells were treated with 100 nM Bafilomycin A1 in cell culture medium or EBSS for 2 hours.

**CRISPR/Cas9-mediated gene editing**

The Zhang online CRISPR design tool (http://crispr.mit.edu/) was used to identify suitable gRNA targets. gRNAs were ordered as pairs of complementary oligos (Sigma-Aldrich) with the sequences 5′-CACCGN20-3′ and 5′-AAACN20C-3′, which were annealed and cloned into the Bbsl site of the appropriate Cas9/gRNA delivery vector.

For the AP4E1 knockout HeLa cell line we inactivated all copies of the AP4E1 gene using the ‘double nickase’ CRISPR/Cas9 system. Paired gRNAs targeting exon 6 of AP4E1 (ENST00000261842: CTTGATTAGGAGCAATGAGA and GCACTTTGTGACAGAGATGT) were individually cloned into pX335-U6-Chimeric_BB-BBh-hSpCas9n(D10A) vectors (a gift from Feng Zhang; Addgene plasmid #42335). HeLa M cells were transfected with both pX335 plasmids and pIRESpuro (Clontech) in a ratio of 2:2:1. Forty-eight hours later, untransfected cells were killed off by a 4-day selection in 1 µg/mL puromycin. Single cell clones were isolated and tested for knockout of AP4E1 by western blotting and immunofluorescence. Clone x6C3 was negative for AP4E1 expression in both assays and was further validated by sequencing. Genomic DNA was harvested using a High Pure PCR Template Purification Kit (Roche) and PCR was used to amplify the region around the target sites. The PCR products were then blunt-end cloned (Zero Blunt PCR Cloning Kit; Invitrogen) and 17 clones were sent for Sanger sequencing with the M13_F primer (Beckman Coulter Genomics).

For knockout of AP4B1 and AP4E1 in SH-SY5Y cells, a lentiviral CRISPR/Cas9 system was used, as described. Lentivirus was produced by transfecting HEK 293ET cells with the lentiviral vector plus the packaging plasmids pCMVΔR8.91 and pMD.G in a ratio of 10:7:3,
using TransIT-293 Transfection Reagent. Harvest of viral supernatants, lentiviral transductions and selection for stable expression (150 μg/mL hygromycin or 3 μg/mL puromycin) were performed as described above for retroviral transductions. Wild-type Cas9 was stably introduced into SH-SY5Y cells using the lentiviral vector pHRSIN-P<sub>SFFV</sub>-FLAG-Cas9-<br>P<sub>PGK</sub>-Hygro (a gift from Paul Lehner, University of Cambridge). Cas9-expressing SH-SY5Y cells were then transduced with gRNAs targeting exon 2 of AP4B1 (ENST00000369569.5: GACCCCAATCCAATGGTGCG) or exon 6 of AP4E1 (ENST00000261842.9: GCACCTTTGTGACAGAGATGT), cloned into the lentiviral sgRNA expression vector pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (a gift from Kosuke Yusa; Addgene #50946<sup>60</sup>). Mixed populations of cells were selected for stable expression of Cas9 and gRNA and knockouts were assessed at the protein level by western blotting.

For CRISPR/Cas9-mediated endogenous tagging of SERINC1 and SERINC3, we used homology-directed repair to introduce a myc-Clover tag at the C-terminus of each protein. Suitable sgRNA targets were selected to enable Cas9 to cut downstream and proximal to the STOP codon of SERINC1 (ENST00000339697.4: ATACACAACCTTACAAAGT) and SERINC3 (ENST00000342374.4: GGTATATGGGGTTTCGGTGA). gRNAs were cloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 vectors (a gift from Feng Zhang; Addgene plasmid #42230<sup>57</sup>), containing cDNA for wild-type Cas9. To generate the homology-directed repair plasmids we made use of a pDonor_myc-Clover plasmid which was a gift from Dick van den Boomen and Paul Lehner (University of Cambridge). This was created using a plasmid gifted to them by Matthew Porteus and Ron Kopito (Stanford University), originally containing a TAP-tag, which was replaced with myc-Clover cloned from pcDNA3.1-Clover-mRuby2 (a gift from Kurt Beam; Addgene #49089<sup>61</sup>). pDonor_myc-Clover contains a 5′ homology region, followed by myc-Clover, a 3′ homology region, an internal ribosome entry site and then a puromycin...
resistance gene. The existing homology regions were replaced with regions specific for SERINC1 (ENSG00000111897: 5’ – 806 bp preceding the STOP codon; 3’ – 814 bp starting 161 bp after the STOP codon) or SERINC3 (ENSG00000132824: 5’ – 835 bp preceding the STOP codon; 3’ – 817 bp starting 95 bp after the STOP codon). 3’ homology regions were chosen to avoid the gRNA target sites. HeLa M cells were transfected with the pX330 and pDonor plasmids in a ratio of 1:1. Forty-eight hours later selection for stable expression of the puromycin resistance gene (meaning incorporation of the Clover tag) was initiated. Single cell clones were isolated and tested for knock-in of Clover by western blotting and immunofluorescence with an anti-GFP antibody. Clones SERINC1-Clover A3 and SERINC3-Clover B6 were positive for Clover expression in both assays and correct integration of the tag was confirmed by Sanger DNA sequencing.

**Fluorescence microscopy**

Cells were grown onto 13 mm glass coverslips and fixed in 3% formaldehyde in PBS (137 mm NaCl, 2.7 mm KCl, 10 mm Na$_2$HPO$_4$ and 1.76 mm KH$_2$PO$_4$, pH 7.4) or, for AP4E1 labelling, ice-cold methanol. Formaldehyde fixed cells were permeabilised with 0.1% saponin and blocked in 1% BSA/0.01% saponin in PBS. Methanol fixed cells were blocked in 0.5% BSA. Primary antibody (diluted in BSA block) was added for 45 minutes at room temperature. Coverslips were washed three times in BSA block and then fluorochrome-conjugated secondary antibody was added in block for 30 minutes at room temperature. Coverslips were then washed three times in PBS, followed by a final wash in dH$_2$O, before being mounted in ProLong Diamond Antifade Reagent with DAPI (Thermo Fisher Scientific). Widefield images were captured on an Axio Imager II microscope (63×/1.4 NA oil immersion objective; AxioCam 506 camera; ZEISS) and confocal and Airyscan enhanced resolution
images were captured on an LSM880 confocal microscope with Airyscan (63×/1.4 NA oil immersion objective; ZEISS), both equipped with ZEN software (ZEISS). Airyscan images were taken in SR (super resolution) mode and raw data were processed using Airyscan processing in “auto strength” mode (strength = 6.0) with Zen Black software version 2.3. Quantification of SERINC1/3-Clover and ATG9A colocalisation was performed on Airyscan images. Colocalisation was measured using Pearson’s Correlation Coefficient with Costes thresholding method (Volocity software 6.3; Perkin Elmer), in a peripheral 10 μm² area in each cell, selected while viewing the green channel only. A minimum of 19 cells were analysed for each condition. For statistical analysis data were analysed by an unpaired two-tailed t-test.

For automated imaging of ATG9A localisation and LC3B puncta, cells were plated in 96-well microplates (6005182, Perkin Elmer), which were either uncoated or for the LC3B assay coated with poly-D-lysine. Cells were fixed in 3% formaldehyde in PBS, permeabilised with 0.1% saponin and labelled for immunofluorescence as described above. After washing off secondary antibody, cells were stained with HCS CellMask™ Blue stain (Thermo Fisher Scientific) diluted 1:5000 in PBS for 30 minutes at room temperature. Cells were then washed three times in PBS before imaging using a CellInsight CX7 High-Content Screening Platform (Olympus 20x/0.4NA objective; Thermo Fisher Scientific) running HCS Studio™ 3.0 software. Autofocus was applied using the whole cell mask channel (channel 1). Experiments were performed in biological triplicate with a technical triplicate (three separate wells per cell line) within each experiment. ATG9A localisation was quantified using the Colocalization Bioapplication V4 (Cellomics, Thermo Fisher Scientific), using anti-TGN46 to segment the TGN (channel 2; ROI_B). ROI_A was defined by the whole cell mask (channel 1) minus ROI_B. The average intensity of anti-ATG9A (channel 3; target 1) was then
quantified in the two regions and a ratio calculated between the two. Ratios were normalised to the mean wild-type ratio. At least 1400 cells were scored per cell line in each experiment. For statistical analysis data were log transformed and analysed by one-way ANOVA with Dunnett’s Multiple Comparison Test. LC3B puncta were quantified using the Spot Detector Bioapplication V4 (Cellomics, Thermo Fisher Scientific). Spots were identified with smoothing on (uniform; value = 1), with the detection method Box (value = 1) and ThreeSigma thresholding (value = 0.012). Spot total count and average area (in μm²) were measured. At least 500 cells were scored per cell line in each experiment. For statistical analysis data were analysed by one-way ANOVA with Dunnett’s Multiple Comparison Test.

Statistical analyses of imaging data were performed using GraphPad Prism version 5.01 (GraphPad Software).

**Correlative light and electron microscopy (CLEM)**

HeLa GFP-RUSC2 (clone 3) cells were mixed with wild-type HeLa cells and seeded on alpha-numeric gridded glass-bottom coverslips (P35G-1.5-14-C-GRID, MatTek) to be 40-50% confluent at the time of fixation. Cells were fixed with 2% formaldehyde/2.5% glutaraldehyde/0.1 M cacodylate buffer for 30 minutes at room temperature and washed with 0.1 M cacodylate. Cells were then stained with Hoechst (to stain the nucleus) for 2 minutes, before being washed with 0.1 M cacodylate. GFP-RUSC2 fluorescence signal was imaged on an LSM780 confocal microscope (63×/1.4 NA oil immersion objective; ZEISS) and the coordinates of cells selected for imaging were recorded. To prepare for electron microscopy cells were secondarily fixed with 1% osmium tetroxide/1.5% potassium ferrocyanide and then incubated with 1% tannic acid in 0.1 M cacodylate to enhance membrane contrast. Samples were washed with dH₂O and dehydrated using increasing
concentrations of ethanol. Epoxy resin (Araldite CY212 mix, Agar Scientific) was mixed at a 1:1 ratio with propylene oxide and this was used for one hour to infiltrate the samples with resin, following which it was replaced with neat Epoxy resin. Pre-baked resin stubs were inverted over coordinates of interest, resin was cured overnight at 65°C, following which stubs were removed from coverslips using liquid nitrogen. Areas of interest were identified by alpha-numeric coordinates and 70 nm ultrathin sections were collected using a Diatome diamond knife attached to an ultracut UCT ultramicrotome (Leica). As areas of interest were at the very basal surfaces of cells (and so the very top of the resin stub), sections were immediately collected onto piloform-coated slot grids. Sections were stained with lead citrate before being imaged on a Tecnai Spirit transmission electron microscope (FEI) at an operating voltage of 80 kV. HeLa GFP-RUSC2 and wild-type cells were imaged, and peripheral accumulations of uncoated vesicular and tubular structures were only observed in the regions of HeLa GFP-RUSC2 cells that correlated with the GFP fluorescence.

**Western blotting**

Estimations of protein concentrations were made using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Cells were lysed for western blot analysis in 2.5% (w/v) SDS/50 mM Tris, pH 8.0. Lysates were passed through a QIAshredder column (Qiagen) to shred DNA, incubated at 65°C for 3 minutes and then boiled in NuPAGE LDS Sample Buffer (Thermo Fisher Scientific). Samples were loaded at equal protein amounts for SDS–PAGE, performed on NuPAGE 4–12% Bis–Tris gels in NuPAGE MOPS SDS Running Buffer, or for LC3B blots, on NuPAGE 12% Bis-Tris gels in NuPAGE MES SDS Running Buffer (all Thermo Fisher Scientific). PageRuler Plus Prestained Protein Ladder (Thermo Fisher Scientific) was used to estimate the molecular size of bands. Proteins were transferred to nitrocellulose
membrane by wet transfer and membranes were blocked in 5% w/v milk in PBS with 0.1% v/v Tween-20 (PBS-T). Primary antibodies (diluted in 5% milk) were added for at least 1 hour at room temperature, followed by washing in PBS-T, incubation in secondary antibody (also in 5% milk) for 30 minutes at room temperature, washing in PBS-T and finally PBS. Chemiluminescence detection of HRP-conjugated secondary antibody was carried out using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) and X-ray film.

**Protein expression and purification for GST pulldowns**

Human AP4E1 (residues 881-1135) and AP4B1 (residues 612-739) appendage domains were expressed as GST-fusion proteins in BL21(DE3)pLysS cells (Invitrogen) for 16-20 hours at 22°C after induction with 0.4 mM IPTG. Proteins were purified in 20 mM HEPES pH 7.5, 200 mM NaCl, and 2 mM 2-Mercaptoethanol. Cells were lysed using a disruptor (Constant Systems Limited) and proteins were affinity purified using glutathione sepharose (GE Healthcare). Fusion proteins were eluted in buffer with 30 mM reduced glutathione and further purified by gel filtration on a Superdex S200 preparative column (GE Healthcare).

**GST pulldowns from cytosol**

All steps were performed on ice with pre-chilled ice-cold buffers, unless otherwise noted.

To prepare cytosol for pulldowns, HeLa cells stably expressing EGFP or GFP-RUSC2 (clone 3), each in two 15 cm plates, were washed in PBS and then cytosol buffer (20 mM HEPES pH 7.5, 150 mM NaCl) and scraped in a total volume of 800 µL cytosol buffer plus 2 mM DL-Dithiothreitol (DTT, D5545, Sigma Aldrich). Cells were transferred to a 1 mL Dounce homogeniser (Wheaton) and homogenised with 15 strokes with the tight pestle, followed by
10 passes through a 30.5 gauge needle. Homogenates were then centrifuged at 38,000 rpm (78438 g RCF max) in a TLA-110 rotor (Beckman Coulter) for 30 minutes to pellet cell debris and the supernatants (cytosol) transferred to new tubes, snap frozen in liquid nitrogen, before storage at -80°C until use in the pulldown assay.

For the pulldowns with AP-4 appendage domains, glutathione sepharose 4B (GE Healthcare) resin was batch equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT. The 50% resin slurry (60 µL) was incubated and rotated with 50 µg of GST, GST-AP4E1, or GST-AP4B1 appendage for 1 hour at 4°C. Equal total protein amounts of HeLa lysates containing GFP-RUSC2 were added independently to each bait sample. Samples were incubated and rotated for 1 hour at 4°C. Samples were centrifuged at 2500 g for 5 minutes. Supernatant was removed, and resin was washed with 1 mL of wash buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 0.5% NP-40) for a total of 3 washes. After final removal of supernatant, 65 µL elution buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 60 mM reduced glutathione) were added to each sample and incubated for 10 minutes at 4°C. Samples were centrifuged at 5000 g for 5 minutes, then supernatant was removed and transferred to a new tube. 10 µL fresh 1M DTT and 25 µL SDS loading dye were added, and samples were boiled at 95°C for 10 minutes. Control HeLa lysates containing GFP were treated in the same way as a control.
**Immunoprecipitations**

All steps were performed on ice with pre-chilled ice-cold buffers, unless otherwise noted.

For sensitive immunoprecipitation of TEPSIN-GFP, wild-type HeLa cells (control) and HeLa cells stably expressing TEPSIN-GFP were grown in SILAC media. For two replicates (data shown in Figure 2E) the wild-type cells were heavy labelled and the TEPSIN-GFP cells light labelled. A third replicate was performed with a label swap and used to filter out unlabelled proteins from the data. For each cell line, two 100 mm plates were washed once in PBS (without CaCl$_2$ and MgCl$_2$; 14190–094, Thermo Fisher Scientific) and then scraped in 4 mL PBS. Cells were transferred to a Dounce homogeniser (Sartorius) and homogenised with 20 strokes with the tight pestle, followed by two passes through a 21 gauge needle. Triton-TX-100 was added to the cells to a final concentration of 0.01%, cells were incubated at 4 °C for 20 minutes with rotation, and homogenates were cleared by centrifugation at 4,000 g for 10 minutes. A portion of each homogenate was retained as input and the remainder was incubated with GFP-Trap A beads (ChromoTek) at 4 °C for 3 hours with rotation. Beads were washed five times with 0.01% Triton-TX-100 and then immunoprecipitates were eluted in 100 μL 2.5% (w/v) SDS/50 mM Tris, pH 8.0 and heated at 65 °C for 5 minutes. Beads were pelleted and supernatants (immunoprecipitates) transferred to new tubes. Equal volumes of control and TEPSIN-GFP immunoprecipitates were mixed and in-solution tryptic digest and peptide purification (single shot) were performed as described below.

For conventional immunoprecipitation, wild type or TEPSIN-GFP expressing cells were SILAC labelled (in duplicate, with label-swap). For harvesting, cells from 2 x 500 cm$^2$ dishes (per IP) were washed twice in PBS, scraped into 10 mL of PBS-TT (PBS, 0.2% (v/v) Triton X-100, 0.1% (v/v) Tween-20), and incubated for 25 minutes with rotation. Insoluble
material was removed by centrifugation at 4,800 g for 3 minutes, followed by centrifugation at 21,000 g for 20 minutes. The supernatant was then further cleared by filtration through a 0.22 μm syringe filter. Lysates were pre-absorbed against Protein A sepharose beads. Approximately 60 μg of rabbit polyclonal anti-GFP antibody (a gift from Matthew Seaman) was added to cleared lysates. After incubation at 4°C for 90 minutes with rotation, 50 μL of Protein A sepharose beads were added, and samples were incubated for a further 45 minutes. Beads were washed four times in PBS-T, once in PBS, and immunoprecipitates recovered in 100 mL Soft Elution Buffer (0.2% (w/v) SDS, 0.1% (v/v) Tween-20, 50 mM Tris-HCl, pH 8.0) by incubation for 7 minutes at 25°C. Eluates from TEPSIN-GFP expressing and wild type control cells were then combined prior to acetone precipitation and analysis by mass spectrometry.

For immunoprecipitation of GFP-RUSC2, wild-type and AP4B1 knockout HeLa cells stably expressing GFP-RUSC2 (mixed populations), and parental wild-type HeLa cells, in 100 mm plates were washed once in PBS and then scraped in 500 μL GFP-trap lysis buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 0.5% NP-40), supplemented with cOmplete™ EDTA-free protease inhibitor (Sigma-Aldrich). Cells were incubated on ice in lysis buffer for 10 minutes and then lysates were cleared by centrifugation at 16,000 g for 10 minutes. A protein assay was performed and, if required, lysates were adjusted to equal protein concentrations with lysis buffer. A portion of each lysate was retained as input and the remainder was incubated with GFP-Trap A beads at 4°C for 3 hours with rotation. Beads were washed five times with GFP-trap lysis buffer and then boiled in NuPAGE LDS Sample Buffer at 75°C for 10 minutes to prepare for western blot analysis.
**BioID streptavidin pulldowns**

All steps were performed on ice with pre-chilled ice-cold buffers, unless otherwise noted.

Streptavidin pulldowns for BioID were carried out from HeLa cells stably expressing BirA*-tagged AP4B1/E1/M1/S1 and control wild-type HeLa, HeLa BirA* and HeLa GFP-BirA* cells, in triplicate (experiments performed on three separate days). Cells were cultured in the presence of 50 µM biotin for 24 hours prior to performing the experiment. Cells were harvested by scraping into 5 mL PBS, pelleted (600 g, 5 minutes) and washed twice in PBS. Lysis was performed in 1 mL RIPA buffer (TBS (50 mM Tris-HCl pH 7.4, 150 mM NaCl), 1% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS) supplemented with cOmplete™ EDTA-free protease inhibitor. DNA was sheared by running the lysates ten times through a 25 gauge needle, lysates were incubated at 4 °C for 10 minutes with mixing and then were sonicated (three times 5 seconds bursts with an amplitude of 10 microns). Lysates were cleared by centrifugation (16,000 g, 15 minutes) and supernatants transferred to new tubes and normalised to cell pellet weight with RIPA buffer. Biotinylated proteins were affinity purified using Pierce High Capacity Streptavidin Agarose (Thermo Fisher Scientific) by incubating with the lysates for 3 hours with rotation at 4°C. Beads were then pelleted and washed three times in RIPA buffer, twice in TBS and three times in 50 mM ammonium bicarbonate (ABC) pH 8 (09830, Sigma Aldrich), before resuspension in 50 mM ABC. Proteins were then reduced by the addition of 10 mM DTT at 56°C for 30 minutes and alkylated by the addition of 55 mM iodoacetamide (1149, Sigma Aldrich) at room temperature for 20 minutes in the dark. Proteins were enzymatically digested by addition of 1 µg Trypsin (V5280, Promega; stock at 0.1 mg/mL in 1 mM HCl) and overnight incubation at 37°C. The following day the beads were pelleted, tryptic peptides (supernatant) collected, spiked with
1 μL 100% trifluoroacetic acid (TFA), dried almost to completion in a centrifugal vacuum concentrator (Concentrator 5301, Eppendorf) and then stored at -20°C. Later samples were thawed, resuspended in a total volume of 100 μL 1% (v/v) TFA and purified on SDB-RPS stage tips (single shot) as described below.

**Preparation of vesicle-enriched fractions**

For the comparative proteomic profiling of the vesicle fraction of AP-4-depleted cells, vesicle-enriched fractions were prepared from paired SILAC-labelled control and AP-4-depleted HeLa cell lines: wild-type versus AP4B1 knockout (two experiments), wild-type versus AP4E1 knockout (two experiments), wild type (untreated) versus AP-4 knockdown (three experiments), control (untreated) versus AP-4 knocksideways for 60 minutes (two experiments).

Vesicle-enriched fractions were prepared essentially as previously described\(^{18}\). All steps were performed on ice with pre-chilled ice-cold buffers, unless otherwise noted. For each sample eight confluent 15 cm dishes of cells were washed with PBS and scraped in a total volume of 7.5 mL Buffer A (0.1 M MES, pH 6.5, 0.2 mM EGTA and 0.5 mM MgCl\(_2\)). Cells were homogenised with 20 strokes of a motorised Potter-Elvehjem homogeniser (or a hand-held Dounce homogenizer with tight pestle) and cell debris was removed by centrifugation at 4,150 g for 32 minutes. Supernatants were treated with 50 μg/mL ribonuclease A (MP Biomedicals) for 1 hour and then partially digested ribosomes were pelleted by centrifugation (4,150 g for 3 minutes) and discarded. Membranes were pelleted by centrifugation at 55,000 rpm (209,900 g RCF\(_{\text{max}}\)) for 40 minutes in an MLA-80 rotor (Beckman Coulter). Membrane pellets were resuspended in 400 μL Buffer A using a 1 mL Dounce homogeniser, mixed with an equal volume of FS buffer (12.5% [w/v] Ficoll and
12.5% [w/v] sucrose, in buffer A) and centrifuged at 20,000 rpm (21,700 g RCFmax) for 34 minutes in a TLA-110 rotor, to pellet contaminants. Supernatants were diluted with four volumes of Buffer A and centrifuged at 40,000 rpm (86,700 g RCFmax) in a TLA-110 rotor for 30 minutes to obtain the vesicle-enriched fraction (pellet). Pellets were resuspended in 50 μL 2.5% SDS (in 50 mM Tris pH 8), heated at 65°C for 3 minutes and centrifuged to pellet insoluble material (16,000 g, 1 minute). For mass spectrometry, equal amounts of protein (20-50 μg) from paired SILAC-labelled control and AP-4-depleted vesicle fractions were mixed and either processed by in-solution or in-gel tryptic digest as described below.

**Generation of Dynamic Organellar Maps**

Organellar maps were prepared as previously described in detail\(^{19}\), from wild-type (control), *AP4B1* knockout and *AP4E1* knockout HeLa cells, in duplicate (six maps in total). Maps were prepared on two separate days, with a complete set of three on each occasion (one control, one *AP4B1* knockout, and one *AP4E1* knockout). In brief, HeLa cells were lysed mechanically, and post-nuclear supernatants were subfractionated into five fractions by a series of differential centrifugation steps. In parallel, a single membrane fraction was obtained from metabolically ‘heavy’ labelled cells (SILAC method). This fraction served as an internal reference, by spiking it into each of the “light” subfractions. Analysis by mass spectrometry provided a ratio of enrichment/depletion for each protein in each subfraction, relative to the standard. All five ratios combined yielded an abundance distribution profile for each protein across the subfractions. Principal component analysis revealed which proteins had similar fractionation profiles (apparent as organellar clusters in Fig. 1g-i).
In-solution digestion of proteins

Protein was precipitated by the addition of 5 volumes of ice-cold acetone, incubated at -20°C for 30 minutes and pelleted by centrifugation at 4°C for 5 minutes at 10,000 g. Precipitated protein was rinsed in ice-cold 80% acetone and re-pelleted as above. All subsequent steps were performed at room temperature. Precipitated protein pellets were air-dried for 5 minutes, resuspended in digestion buffer (50 mM Tris pH 8.1, 8 M Urea, 1 mM DTT) and incubated for 15 minutes. Protein was alkylated by addition of 5 mM iodoacetamide for 20 minutes and then enzymatically digested by addition of LysC (V1071, Promega; 1 mg per 50 mg of protein) for at least 3 hours. Digests were then diluted four-fold with 50 mM Tris pH 8.1 before addition of Trypsin (1 mg per 50 mg of protein) for an overnight incubation. The peptide mixtures were then acidified to 1% (v/v) TFA in preparation for peptide purification and fractionation.

Peptide purification and fractionation

Several different peptide fractionation and clean-up strategies were used in this study. For most mass spectrometric experiments, peptides were purified and fractionated on SDB-RPS (#66886-U, Sigma) stage tips as previously described. Briefly, peptide mixtures in 1% TFA were loaded onto activated stage-tips and washed with Proteomics Wash Buffer (Preomics) and then 0.2% (v/v) TFA. For single shot analysis, peptides were eluted with 60 µL Buffer X (80% (v/v) acetonitrile, 5% (v/v) ammonium hydroxide). For triple-fractionation, peptides were eluted successively using 20 µL SDB-RPSx1 (100 mM ammonium formate, 40% (v/v) acetonitrile, 0.5% (v/v) formic acid), then 20 µL SDB-RPSx2 (150 mM ammonium formate, 60% (v/v) acetonitrile, 0.5% formic acid), then 30 µL Buffer X. For six-fold fractionation, peptides were processed by strong cation exchange (SCX) on stage tips as
previously described\textsuperscript{63}. Alternatively, protein samples were separated by SDS-PAGE, gels were cut into 5-10 slices, and proteins were digested with trypsin in-gel as described\textsuperscript{64}. Cleaned peptides were dried almost to completion in a centrifugal vacuum concentrator, and then volumes were adjusted to 10 µL with Buffer A\textsuperscript{*} (0.1% (v/v) TFA, 2% (v/v) acetonitrile) and either immediately analysed by mass spectrometry, or first stored at -20°C.

The following techniques were applied for the various mass spectrometric analyses of this study: single shot SDB-RPS: BioID samples and sensitive IPs; triple-fractionation SDB-RPS: organellar maps analyses, membrane proteome analysis, vesicle prep analyses (AP-4 knockouts); six-fraction SCX: whole cell lysate full proteome analysis; in-gel digestion with multiple gel slice fractions: vesicle prep analyses (AP-4 knockdown, AP-4 knocksideways), conventional IPs.
Mass spectrometry

Overview of mass spectrometric analyses

| Sample                          | MS Quant Strategy | Number of replicates | Sample fractionation approach | MS instrument | Number of MS runs[^1] |
|---------------------------------|-------------------|----------------------|-------------------------------|---------------|-----------------------|
| Dynamic organellar maps[^2]     | SILAC             | 2 x Wild-type        | 3 x SDB-RPS                   | Exactive HF   | 30                    |
|                                 |                   | 2 x AP4E1 KO         |                               |               | 30                    |
|                                 |                   | 2 x AP4B1 KO         |                               |               | 30                    |
| Whole cell lysates              | SILAC             | 3 x Wild-type        | 6 x SCX                       | Exactive HF   | 18                    |
|                                 |                   | 3 x AP4E1 KO         |                               |               | 18                    |
|                                 |                   | 3 x AP4B1 KO         |                               |               | 18                    |
| Membrane fractions              | LFQ               | 3 x Wild-type        | 3 x SDB-RPS                   | Exactive HF   | 9                     |
|                                 |                   | 3 x AP4E1 KO         |                               |               | 9                     |
|                                 |                   | 3 x AP4B1 KO         |                               |               | 9                     |
| Vesicle preparations            | SILAC             | 3 x AP-4 KD          | 10 gel slices                 | Exactive      | 37[^3]                |
|                                 |                   | 2 x AP-4 KS          | 10 gel slices                 |               | 20                    |
|                                 |                   | 2 x AP4E1 KO         | 3 x SDB-RPS                   | Exactive HF   | 9[^3]                 |
|                                 |                   | 2 x APEB1 KO         | 3 x SDB-RPS                   | Exactive HF   | 6                     |
| Sensitive IPs                   | SILAC             | 3 x TEPSIN-GFP       | 1 x SDB-RPS                   | Exactive HF   | 4[^3]                 |
| Conventional IPs                | SILAC             | 2 x TEPSIN-GFP       | 2 x 5 gel slices              | Exactive      | 20                    |
| BioID                           | LFQ               | 3 x AP4B1-BirA*      | 1 x SDB-RPS                   | Exactive HF   | 3                     |
|                                 |                   | 3 x AP4E1-BirA*      |                               |               | 3                     |
|                                 |                   | 3 x AP4M1-BirA*      |                               |               | 3                     |
|                                 |                   | 3 x AP4S1-BirA*      |                               |               | 3                     |
|                                 |                   | 3 x HeLa (control)   |                               |               | 3                     |
|                                 |                   | 3 x BirA* (control)  |                               |               | 3                     |
|                                 |                   | 3 x GFP-BirA* (control) |                        |               | 3                     |
| **Total number of MS samples**  |                   |                      |                               |               | **288**               |
| **Total MS run time**           |                   |                      |                               |               | **30 days**           |

[^1] Each run took approximately 150 minutes (HPLC gradient) + 25 minutes loading.

[^2] Each map consisted of five samples (subfractions).

[^3] Includes some technical replicates.
MS Instrumentation and configuration

Two different mass spectrometers were used (Q-Exactive HF and Q-Exactive; Thermo Fisher Scientific), as indicated in the summary table above. Mass spectrometric analyses were performed as previously described in detail (for Q-Exactive HF\textsuperscript{19,20} and for Q-Exactive\textsuperscript{64}).

Processing of mass spectrometry data

Mass spectrometry raw files were processed in MaxQuant\textsuperscript{65} version 1.5, using the human SwissProt canonical and isoform protein database, retrieved from UniProt (www.uniprot.org). For SILAC experiments (vesicle fractions; Dynamic Organellar Map subfractions; whole cell lysate analysis; TEPSIN-GFP immunoprecipitations) multiplicity was set to 2, with Lys8 and Arg10 selected as heavy labels; Re-quantify was enabled; minimum number of quantification events was set to 1. For label-free experiments (membrane fractions; BioID) multiplicity was set to 1; LFQ was enabled, with LFQ minimum ratio count set to 1. Membrane fractions were SILAC heavy labelled (Arg10, Lys8). Matching between runs was enabled. Default parameters were used for all other settings.

Proteomic data analysis

All analyses were performed on the ‘protein groups’ file output from MaxQuant. Data transformation, filtering and statistical analyses were performed in Perseus software\textsuperscript{66} version 1.5 and Microsoft Excel. Principal Component Analysis (PCA) was performed in SIMCA 14 (Umetrics/MKS). PCA plots (Fig. 1g-i and 2b) show projections along 1\textsuperscript{st} and 3\textsuperscript{rd} principal components, for optimum visualisation. For all experiments identifications were
first filtered by removing matches to the reverse database, matches based on modified peptides only, and common contaminants (‘standard filtering’). Further experiment-specific filtering, data transformation and analyses were performed as described below.

**Dynamic Organellar Maps statistical analysis**

To identify proteins with shifted subcellular localisation in response to AP-4 knockout, we applied our previously described rigorous statistical analysis\textsuperscript{19,20}. We adapted the procedure to the experimental design of the present study as follows. Organellar maps were made in duplicate, from control, \textit{AP4B1} knockout, and \textit{AP4E1} knockout cells. Abundance distribution profiles across all six maps were determined for 3,926 proteins. First, the profiles obtained in the \textit{AP4B1} knockout and \textit{AP4E1} knockout cells were subtracted from the profiles obtained in the cognate control map, protein by protein, to obtain 2 x 2 sets of delta profiles (Con\textsubscript{1}-AP4B1\textsubscript{1}, Con\textsubscript{2}-AP4B1\textsubscript{2}; Con\textsubscript{1}-AP4E1\textsubscript{1}, Con\textsubscript{2}-AP4E1\textsubscript{2}). For proteins that do not shift, the delta profile should be close to zero. All delta profile sets were subjected to a robust multivariate outlier test, implemented in Perseus software\textsuperscript{66}, to identify proteins with delta profiles significantly different from experimental scatter. The profile distance corresponds to a \textit{p}-value reflecting how likely it is to observe this deviation by chance, assuming no real change. For each protein, four such \textit{p}-values were hence obtained, two from \textit{AP4E1} knockout, and two from \textit{AP4B1} knockout. For maximum stringency, we selected the least significant of these \textit{p}-values as representative of a protein’s shift. A shift of equal or greater significance was thus observed in all four comparisons. We did not treat the four delta maps as completely independent though, since both knockouts were compared to the same cognate control. Hence, as a very conservative measure of movement, the selected \textit{p}-value was only squared (instead of being raised to the power of four), and then corrected for multiple hypothesis testing using the Benjamini
Hochberg Method. The negative $\log_{10}$ of the corrected $p$-value corresponded to a protein’s movement (M) score.

Next, the reproducibility of observed delta profiles across replicates was determined as the Pearson correlation ($\Delta$map (Con_1-AP4B1_1) vs $\Delta$map (Con_2-AP4B1_2); and $\Delta$map (Con_1-AP4E1_1) vs $\Delta$map (Con_2-AP4E1_2)). For maximum stringency, we chose the lower one of the two obtained correlations as representative of the protein’s shift reproducibility, corresponding to its R score.

To control the false discovery rate (FDR), we then applied the same analysis to our previously published wild-type HeLa maps$^{19}$ (six untreated maps with no genuine protein shifts expected). In this mock experiment, we designated two maps as controls, two as ‘mock knockout 1’, and two as ‘mock knockout 2’. As above, we calculated M and R scores from the lowest correlations and $p$ values of movement. The estimated FDR at a given set of M and R score cut offs was then calculated as the number of hits obtained with the mock experiment data, divided by the number of hits obtained with the AP-4 maps data, scaled by the relative sizes of the datasets (which were almost identical). At the chosen high stringency cut-offs (M score >4, R score >0.81), not a single hit was obtained from the mock data. Hence, we estimate the FDR for the three hits obtained from the AP-4 maps at <1%.

Finally, as an additional criterion, we also evaluated the similarity of identified shifts across the two different knockouts (i.e. the correlation of $\Delta$map (Con_1-AP4B1_1) vs $\Delta$map (Con_1-AP4E1_1); and $\Delta$map (Con_2-AP4B1_2) vs $\Delta$map (Con_2-AP4E1_2)). All three hits showed a very high degree of shift correlation (>0.9) across the two AP-4 knockout lines, thus also passing the additional stringency filter.
**Membrane fraction analysis**

Relative protein levels in membrane fractions from *AP4B1* knockout and *AP4E1* knockout HeLa cells (each in triplicate) were compared to those in membrane fractions from wild-type HeLa cells (in triplicate) using LFQ intensity data. The primary output was a list of identified proteins, and for each protein up to nine LFQ intensities across the wild-type and AP-4 knockout samples. Following standard data filtering, proteins were filtered to only leave those with nine LFQ intensities (no missing values allowed), leaving 6653 proteins. LFQ intensities were then log-transformed and comparison of knockout and wild-type membrane fractions performed with a two-tailed t-test. A permutation-based (1000 permutations) estimated FDR of 0.05 and an S0 parameter of 0.5 were set to define significance cut-offs (Perseus software).

**Whole cell lysate analysis**

Whole cell lysates from light-labelled *AP4B1* knockout and *AP4E1* knockout HeLa cells were compared to lysates from heavy-labelled wild-type HeLa cells by SILAC quantification, each in triplicate. The primary output was a list of identified proteins, and for each protein up to six H/L (Heavy/Light) ratios of relative abundance (three comparing *AP4B1* knockout to wild-type and three comparing *AP4E1* knockout to wild-type). Following standard data filtering, proteins were further filtered to require at least two H/L ratios for each knockout, leaving 6841 proteins. H/L ratios from each replicate were then normalised to the median H/L ratio for that replicate, log-transformed, and inverted to L/H so that a protein depleted from the whole cell lysate in the absence of AP-4 had a negative ratio. A one-sample t-test (two-tailed) was applied to compare the L/H ratios for each protein to zero (null hypothesis of no change between wild-type and knockout). To control the false discovery rate (FDR), an identical analysis of a mock experiment comparing light- and heavy-
labelled wild-type HeLa lysates was performed (in triplicate; no genuine changes were expected here). The FDR was given by the number of hits observed in the mock experiment divided by the number of hits in the knockout experiment. Using the cut-offs $p \leq 0.02$ and a minimum absolute fold change ($\log_2$) of 0.45, the estimated FDR was 25%. The $t$ scores from the mock experiment were calculated from only three datapoints per protein (whereas up to six were used for the knockout vs control data), and hence were adjusted to emulate a 6 datapoint experiment. To this end, we assumed that the observed standard deviations and means had been observed from 6 datapoints, yielding much lower $p$ values from the same $t$ scores for the mock data. This procedure thus likely overestimates the number of false positives at a given cut-off, resulting in highly stringent FDR control.

**Vesicle fraction analysis**

Paired AP-4-depleted and control vesicle fractions were compared by SILAC quantification. The primary output was a list of identified proteins, and for each protein up to nine H/L ratios of relative abundance, and the number of quantification events (H/L ratio count) used to calculate each ratio. Following standard data filtering, proteins were further filtered to require at least one H/L ratio count in all experiments. This excluded AP4S1 due to it having a ratio count of 0 in one experiment, so the data for AP4S1 was manually added back to the dataset (with one missing datapoint), giving a total of 2848 proteins quantified across all experiments. H/L ratios from each experiment were then normalised to the median H/L ratio for that experiment. For experiments in which the control cells were light labelled, normalised H/L ratios were inverted to L/H, and then all ratios were log transformed for plotting, so that depletion from the vesicle fraction in the absence of AP-4 was represented by a positive value. To identify proteins which were consistently lost from
the vesicle fraction from AP-4 depleted cells, the normalised log-transformed SILAC ratios from all nine experiments were scaled to unit variance and combined by PCA.

**TEPSIN-GFP immunoprecipitations**

TEPSIN-GFP immunoprecipitations (conventional and sensitive) were compared to control immunoprecipitations by SILAC quantification. The primary output for each was a list of identified proteins, and for each protein one or more (up to three) H/L ratios of relative abundance between the TEPSIN-GFP and control immunoprecipitations, and the number of quantification events (H/L ratio count) used to calculate each ratio. Following standard data filtering, unlabelled proteins were filtered out based on having an H/L ratio <0.2 in label-swapped replicates. Proteins were further filtered on a minimum H/L ratio count of 1 in all replicates, leaving 585 proteins for the conventional IP and 1128 proteins for the sensitive IP. H/L ratios from each replicate were normalised to the median H/L ratio for that replicate. For replicates in which the control cells were heavy labelled, normalised H/L ratios were inverted to L/H, and then all ratios were log transformed for plotting, so that enrichment in the TEPSIN-GFP immunoprecipitation was represented by positive values. The log SILAC ratios from two replicates were plotted against each other to reveal proteins enriched in the TEPSIN-GFP immunoprecipitations.

**AP-4 BioID**

Relative protein levels were compared across samples using LFQ intensity data. LFQ intensities from pulldowns from the control cell lines (HeLa, HeLa BirA* and HeLa GFP-BirA*) were compressed from nine values (three cell lines in triplicate) to three using control compression as previously described. This creates a “worst-case scenario” control dataset where the three highest LFQ intensities are taken for each protein. Pulldowns from each AP-4 BioID cell line (in triplicate) were then compared to the compressed control dataset.
Proteins were first filtered on LFQ intensities for valid values in all three replicate pulldowns from the AP-4 BioID cell line, leaving between approximately 3100-3700 proteins depending on the subunit. LFQ intensities were then log-transformed, and missing data points were imputed from a normal distribution with a downshift of 2.2 and a width of 0.3 standard deviations. Comparisons between control and AP-4 BioID cell lines were performed with a two-tailed t-test. A permutation-based (250 permutations) estimated FDR of 0.05 and an S0 parameter of 0.5 were set to define significance cut-offs (Perseus software).

**Data availability**

All data supporting this work are available on reasonable request to the corresponding author.
Acknowledgements

We thank Matthias Mann for his continued support of this project, Marco Hein, Dick van den Boomen, and Tom O’Loughlin for advice, the CIMR microscopy core unit for technical expertise, Korbinian Mayr, Igor Paron, and Gabriele Sowa for outstanding technical support, Sebastian Schuck, Paul Luzio, Zuzana Kadlecova, and Paul Manna for critical reading of the manuscript, and CureSPG47 for inspiration. We give special thanks to all members of the Mann Department and Robinson Lab for valuable feedback. This work was funded by the German Research Foundation (DFG/Gottfried Wilhelm Leibniz Prize MA 1764/2-1), the Louis-Jeantet Foundation, the Max Planck Society for the Advancement of Science, a Wellcome Trust Principal Research Fellowship (086598) to M.S.R., an NIH grant (R35GM119525) to L.P.J., an NIHR Cambridge BRC PhD Fellowship to A.K.D., and a Wellcome Trust Strategic Award to the CIMR (100140). L.P.J. is a Pew Scholar in the Biomedical Sciences, supported by the Pew Charitable Trusts. The authors declare no competing financial interests.

Author Contributions

G.H.H.B., M.S.R and A.K.D. conceptualised and designed the experiments. A.K.D. and G.H.H.B. performed and analysed most of the experiments. D.N.I. assisted in proteomic analyses and data visualisation. J.R.E. performed and analysed the CLEM. L.P.J. and T.L.A. performed protein purifications and pulldowns. J.H. assisted in the generation of the knocksideways cell line and provided the patient fibroblasts. A.K.D., G.H.H.B. and M.S.R wrote the original and revised manuscripts, with contributions from the other authors. G.H.H.B. and M.S.R. supervised the project.
References

1. Robinson, M. S. Forty Years of Clathrin-coated Vesicles. *Traffic* **16**, 1210–1238 (2015).
2. Dell’Angelica, E. C., Mullins, C. & Bonifacino, J. S. AP-4, a Novel Protein Complex Related to Clathrin Adaptors. *J. Biol. Chem.* **274**, 7278–7285 (1999).
3. Hirst, J., Bright, N. A., Rous, B. & Robinson, M. S. Characterization of a fourth adaptor-related protein complex. *Mol. Biol. Cell* **10**, 2787–2802 (1999).
4. Hirst, J., Irving, C. & Borner, G. H. H. Adaptor protein complexes AP-4 and AP-5: new players in endosomal trafficking and progressive spastic paraplegia. *Traffic* **14**, 153–164 (2013).
5. Abou Jamra, R. et al. Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. *Am. J. Hum. Genet.* **88**, 788–795 (2011).
6. Verkerk, A. J. M. H. et al. Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. *Am. J. Hum. Genet.* **85**, 40–52 (2009).
7. Moreno-De-Luca, A. et al. Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability. *J. Med. Genet.* **48**, 141–144 (2011).
8. Ebrahimi-Fakhari, D. et al. Clinical and genetic characterization of AP4B1-associated SPG47. *Am. J. Med. Genet. Part A.* 1–8 (2017). doi:10.1002/ajmg.a.38561
9. Blumkin, L., Lerman-Sagie, T., Lev, D., Yosovich, K. & Leshinsky-Silver, E. A new locus (SPG47) maps to 1p13.2-1p12 in an Arabic family with complicated autosomal recessive hereditary spastic paraplegia and thin corpus callosum. *J. Neurol. Sci.* **305**, 67–70 (2011).
10. Tüysüz, B. et al. Autosomal recessive spastic tetraplegia caused by AP4M1 and AP4B1 gene mutation: Expansion of the facial and neuroimaging features. *Am. J. Med. Genet. Part A* **164**, 1677–1685 (2014).
11. Matsuda, S. et al. Accumulation of AMPA receptors in autophagosomes in neuronal axons lacking adaptor protein AP-4. *Neuron* **57**, 730–745 (2008).
12. Burgos, P. V et al. Sorting of the Alzheimer’s disease amyloid precursor protein mediated by the AP-4 complex. *Dev. Cell* **18**, 425–436 (2010).
13. Toh, W. H., Tan, J. Z. A., Zulkefl, K. L., Houghton, F. J. & Gleeson, P. A. Amyloid
precursor protein traffics from the Golgi directly to early endosomes in an Arl5b- and AP4-dependent pathway. *Traffic* **18**, 159–175 (2017).

14. Aguilar, R. C. *et al.* Signal-binding specificity of the mu4 subunit of the adaptor protein complex AP-4. *J. Biol. Chem.* **276**, 13145–13152 (2001).

15. Simmen, T., Höning, S., Icking, A., Tikkanen, R. & Hunziker, W. AP-4 binds basolateral signals and participates in basolateral sorting in epithelial MDCK cells. *Nat. Cell Biol.* **4**, 154–159 (2002).

16. Ross, B. H., Lin, Y., Corales, E. A., Burgos, P. V & Mardones, G. A. Structural and functional characterization of cargo-binding sites on the μ4-subunit of adaptor protein complex 4. *PLoS One* **9**, e88147 (2014).

17. Yap, C. C. *et al.* Adaptor protein complex-4 (AP-4) is expressed in the central nervous system neurons and interacts with glutamate receptor δ2. *Mol. Cell. Neurosci.* **24**, 283–295 (2003).

18. Borner, G. H. H. *et al.* Multivariate proteomic profiling identifies novel accessory proteins of coated vesicles. *J. Cell Biol.* **197**, 141–160 (2012).

19. Itzhak, D. N., Tyanova, S., Cox, J. & Borner, G. H. H. Global, quantitative and dynamic mapping of protein subcellular localization. *Elife* **5**, 1–36 (2016).

20. Itzhak, D. N. *et al.* A Mass Spectrometry-Based Approach for Mapping Protein Subcellular Localization Reveals the Spatial Proteome of Mouse Primary Neurons. *Cell Rep.* **20**, 2706–2718 (2017).

21. Orsi, A. *et al.* Dynamic and transient interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy. *Mol Biol Cell* **23**, 1860–1873 (2012).

22. Robinson, M. S., Sahlender, D. A. & Foster, S. D. Rapid inactivation of proteins by rapamycin-induced rerouting to mitochondria. *Dev. Cell* **18**, 324–331 (2010).

23. Alwadei, A. H. *et al.* Loss-of-function mutation in RUSC2 causes intellectual disability and secondary microcephaly. *Dev. Med. Child Neurol.* **58**, 1317–1322 (2016).

24. Roux, K. J., Kim, D. I., Raida, M. & Burke, B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. *J. Cell Biol.* **196**, 801–810 (2012).

25. Varnaite, R. & MacNeill, S. A. Meet the neighbors: Mapping local protein interactomes by proximity-dependent labeling with BioID. *Proteomics* **16**, 2503–2518
26. Frazier, M. N. et al. Molecular Basis for the Interaction Between AP4 β4 and its Accessory Protein, Tepsin. *Traffic* **17**, 400–415 (2016).

27. Mattera, R., Guardia, C. M., Sidhu, S. S. & Bonifacino, J. S. Bivalent motif-ear interactions mediate the association of the accessory protein tepsin with the AP-4 adaptor complex. *J. Biol. Chem.* **290**, 30736–30749 (2015).

28. Young, A. R. J. et al. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. *J. Cell Sci.* **119**, 3888–3900 (2006).

29. MacDonald, J. I. S. et al. Nesca, a novel neuronal adapter protein, links the molecular motor kinesin with the pre-synaptic membrane protein, syntaxin-1, in hippocampal neurons. *J. Neurochem.* **121**, 861–880 (2012).

30. Xie, Z., Nair, U. & Klionsky, D. J. Atg8 Controls Phagophore Expansion during Autophagosome Formation. *Mol. Biol. Cell* **19**, 3290–3298 (2008).

31. Kong, X. F. et al. A Novel Homozygous p.R1105X Mutation of the AP4E1 Gene in Twins with Hereditary Spastic Paraplegia and Mycobacterial Disease. *PLoS One* **8**, e58286 (2013).

32. Hardies, K. et al. Recessive loss-of-function mutations in AP4S1 cause mild fever-sensitive seizures, developmental delay and spastic paraplegia through loss of AP-4 complex assembly. *Hum. Mol. Genet.* **24**, 2218–2227 (2014).

33. Yamaguchi, J. et al. Atg9a deficiency causes axon-specific lesions including neuronal circuit dysgenesis. *Autophagy* (2017). doi:10.1080/15548627.2017.1314897.

34. Blackstone, C. Cellular pathways of hereditary spastic paraplegia. *Annu. Rev. Neurosci.* **35**, 25–47 (2012).

35. Baas, P. W., Deitch, J. S., Black, M. M. & Banker, G. A. Polarity orientation of microtubules in hippocampal neurons: Uniformity in the axon and nonuniformity in the dendrite. *Proc. Natl. Acad. Sci. U. S. A.* **85**, 8335–8339 (1988).

36. Stavoe, A. K. H., Hill, S. E., Hall, D. H. & Colon-Ramos, D. A. KIF1A/UNC-104 Transports ATG-9 to Regulate Neurodevelopment and Autophagy at Synapses. *Dev. Cell* **38**, 171–185 (2016).

37. Maday, S., Wallace, K. E. & Holzbaur, E. L. F. Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. *J. Cell Biol.* **196**, 407–417 (2012).
38. Maday, S. & Holzbaur, E. L. F. Autophagosome biogenesis in primary neurons follows an ordered and spatially regulated pathway. *Dev. Cell* **30**, 71–85 (2014).

39. Tsuboyama, K. *et al.* The ATG conjugation systems are important for degradation of the inner autophagosomal membrane. *Science* **354**, 1036–1041 (2016).

40. Nezich, C. L., Wang, C., Fogel, A. I. & Youle, R. J. MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5. *J. Cell Biol.* **210**, 435–450 (2015).

41. Lu, S. L. *et al.* Endothelial cells are intrinsically defective in xenophagy of Streptococcus pyogenes. *PLoS Pathog.* (2017). doi:10.1371/journal.ppat.1006444

42. Mari, M. *et al.* An Atg9-containing compartment that functions in the early steps of autophagosome biogenesis. *J. Cell Biol.* **190**, 1005–1022 (2010).

43. Corcelle-Termeau, E. *et al.* Excess sphingomyelin disturbs ATG9A trafficking and autophagosome closure. *Autophagy* **12**, 833–849 (2016).

44. Saitoh, T. *et al.* Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc. Natl. Acad. Sci.* **106**, 20842–20846 (2009).

45. Goodwin, J. M. *et al.* Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9. *Cell Rep.* **20**, 2341–2356 (2017).

46. Bayer, M. *et al.* Identification and characterization of Iporin as a novel interaction partner for rab1. *BMC Cell Biol.* **6**, 15 (2005).

47. Rosa, A. *et al.* HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. *Nature* **526**, 212-217 (2015).

48. Usami, Y., Wu, Y. & Göttlinger, H. G. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. *Nature* **526**, 218–223 (2015).

49. Matheson, N. J. *et al.* Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. *Cell Host Microbe* **18**, 1–15 (2015).

50. Inuzuka, M., Hayakawa, M. & Ingi, T. Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. *J. Biol. Chem.* **280**, 35776–35783 (2005).

51. Trautz, B. *et al.* The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles. *J. Biol. Chem.* **292**, 13702–13713 (2017).
52. Chu, E. P. F. et al. Disruption of Serinc1, which facilitates serine-derived lipid synthesis, fails to alter macrophage function, lymphocyte proliferation or autoimmune disease susceptibility. *Mol. Immunol.* **82**, 19–33 (2017).

53. Simpson, F. et al. A novel adaptor-related protein complex. *J. Cell Biol.* **133**, 749–760 (1996).

54. Biedler, J. L., Roffler-Tarlov, S., Schachner, M. & Freedman, L. S. Multiple Neurotransmitter Synthesis by Human Neuroblastoma Cell Lines and Clones. *CANCER Res.* **38**, 3751–3757 (1978).

55. Ong, S.-E. et al. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics. *Mol. Cell. Proteomics* **1.5**, 376–368 (2002).

56. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nuclease. *Nat. Biotechnol.* **31**, 827–832 (2013).

57. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science* **339**, 819–823 (2013).

58. Ran, F. A. et al. Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity. *Cell* **154**, 1380–1389 (2013).

59. Timms, R. T. et al. Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens. *Nat. Commun.* **7**, 11786 (2016).

60. Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. *Nat. Biotechnol.* **32**, 267–273 (2014).

61. Lam, A. J. et al. Improving FRET dynamic range with bright green and red fluorescent proteins. *Nat. Methods* **9**, 1005–1012 (2012).

62. Antrobus, R. & Borner, G. H. H. Improved elution conditions for native co-immunoprecipitation. *PLoS One* **6**, 2–7 (2011).

63. Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. *Nat. Methods* **11**, 319–324 (2014).

64. Borner, G. H. H. et al. Fractionation profiling: a fast and versatile approach for mapping vesicle proteomes and protein-protein interactions. *Mol. Biol. Cell* **25**, 3178–3194 (2014).
65. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–1372 (2008).

66. Tyanova, S. *et al.* The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* 13, 731–740 (2016).

67. Lambert, J.-P., Tucholska, M., Go, C., Knight, J. D. R. & Gingras, A.-C. Proximity biotinylation and affinity purification are complementary approaches for the interactome mapping of chromatin-associated protein complexes. *J. Proteomics* 118, 81–94 (2015).
Figure Legends

Figure 1. Dynamic Organellar Maps detect mislocalisation of ATG9A, SERINC1 and SERINC3 in AP-4 knockout (KO) HeLa cells. (a) Diagram of the AP-4 complex. (b) Workflow for Dynamic Organellar Map generation. Cell lysates are subjected to a series of differential centrifugation steps, to achieve partial separation of organelles. Proteins in each fraction are quantified by mass spectrometry, to obtain abundance distribution profiles. Proteins associated with the same organelle have similar profiles, and can be classified through cluster analysis. (c) Western blot of whole-cell lysates from wild-type, AP4B1 KO and AP4E1 KO HeLa cells; α-Tubulin, loading control. (d) Experimental design for AP-4 Dynamic Organellar Mapping. Maps were made from wild type, AP4B1 KO and AP4E1 KO cell lines, each in duplicate. Profiles from each KO map were subtracted from the cognate control profiles, to obtain two AP4E1 Δmaps, and two AP4B1 Δmaps. Proteins that did not shift had similar profiles in wild-type and AP-4 KO maps, and hence Δ profiles close to zero. To identify significantly translocating proteins, the magnitude of shift (M) and the reproducibility of shift direction (R) were scored for each protein and each Δmap. (e) MR plot analysis of AP-4 Dynamic Organellar Mapping. 3,926 proteins were profiled across all maps. Three proteins whose subcellular localisation was significantly and reproducibly shifted across the AP-4 KO lines were identified with very high confidence (FDR<1%). The analysis only covered proteins profiled across all maps; since AP-4 itself was not present in the KO maps, it was not included. See also Supplementary Table 1. (f) Topology of the proteins identified by AP-4 Dynamic Organellar Mapping. (g-i) Visualisation of organellar maps by principal component analysis (PCA). Each scatter point represents a protein; proximity indicates similar fractionation profiles. Known organellar marker proteins are
shown in colour, and form clusters. Each plot combines the data from two independent map replicates. 
g: wild-type; h: AP4B1 KO; i: AP4E1 KO. The three proteins that undergo significant shifts in AP-4 KOs are annotated. See also Supplementary Table 2.

Figure 2. Multiple orthogonal proteomic approaches confirm ATG9A, SERINC1 and SERINC3 as AP-4 cargo proteins and identify RUSC1 and RUSC2 as AP-4 accessory proteins. (a) Workflow for proteomic vesicle profiling. Vesicle-enriched fractions were prepared in pairs from metabolically (SILAC heavy or light) labelled control and AP-4-depleted cells, and compared by quantitative mass spectrometry (MS). 2,848 proteins were quantified across all experiments. (b) PCA combining the SILAC ratios from nine comparative AP-4-depleted vesicle fraction experiments. Proteins consistently lost from the vesicle fraction of AP-4-depleted cells are in the top-right section. (c) Domain organisation of RUSC1 and RUSC2. (d) Comparison of protein abundance in total membrane fractions prepared from AP-4 KO (AP4B1 and AP4E1, each in triplicate, n=6) and wild-type HeLa cells (in triplicate, n=3), analysed by label-free quantitative MS. >6,600 proteins were quantified; RUSC1 was the only protein significantly depleted from the membrane fraction of AP-4 KO cells (RUSC2 and AP-4 subunits were not consistently detected). Data were analysed with a two-tailed t-test: volcano lines indicate the significance threshold (FDR=5%). (e) Comparison of protein abundance in affinity purifications of biotinylated proteins from HeLa cells stably expressing AP4E1-BirA*, and control cell lines (HeLa, HeLa BirA* and HeLa GFP-BirA*), analysed by label-free quantitative MS and volcano analysis as in d. The experiment was performed in triplicate and the control dataset was compressed to the three highest LFQ intensities per protein (i.e. high stringency). >3,100 proteins were quantified; FDR=5%. (f) High-sensitivity low-detergent immunoprecipitations from HeLa cells stably expressing the AP-4 associated
protein TEPSIN-GFP. The scatter plot shows two replicate SILAC comparisons of TEPSIN-GFP immunoprecipitations versus mock immunoprecipitations (from parental HeLa). TEPSIN-GFP associated proteins have high ratios. (g) Western blots of GST pulldowns using GST-ε (883-1137), GST-β4 (612-739) or GST, from cytosol from HeLa cells stably expressing GFP-RUSC2, or GFP alone as a control. Input cytosol is also shown. (h) Estimated copy numbers of AP-4 (mean of AP4B1/E1/M1 subunits) and its accessory (TEPSIN, RUSC1/2) and cargo (ATG9A, SERINC1/3) proteins in HeLa cells\textsuperscript{19}. See also Supplementary Fig. 2 and Supplementary Tables 3-5.

**Figure 3.** ATG9A accumulates at the trans-Golgi network (TGN) in AP-4 knockout (KO) HeLa and SH-SY5Y cells. (a) Widefield imaging of immunofluorescence double labelling of ATG9A and TGN46 in wild-type, AP4B1 KO, and AP4B1 KO HeLa cells stably expressing AP4B1 (rescue). Scale bar: 20 μm. (b) Quantification of the ratio of ATG9A labelling intensity between the TGN and the rest of the cell using an automated microscope. Ratios were normalised to the mean wild-type ratio. The experiment was performed in biological triplicate (mean indicated), and >1400 cells were scored per cell line in each replicate. Data were subjected to one-way ANOVA with Dunnett’s Multiple Comparison Test for significant differences from the wild-type: \(* * *\) p ≤ 0.001; ns p > 0.05. (c) SH-SY5Y (neuroblastoma) cells stably expressing Cas9 were transduced with sgRNAs to AP4B1 or AP4E1. Mixed populations were selected for sgRNA expression and parental Cas9-expressing SH-SY5Y cells were used as a control. Western blot of whole-cell lysates; α-Tubulin, loading control. (d) Widefield imaging of immunofluorescence double labelling of ATG9A and TGN46 in control, AP4B1 KO and AP4E1 KO SH-SY5Y cells. Scale bar: 20 μm.
**Figure 4. ATG9A and SERINC colocalisation in peripheral puncta is dependent on AP-4.**

CRISPR/Cas9 gene editing was used to introduce a C-terminal Clover (modified GFP) tag to endogenous SERINC1 or SERINC3 in HeLa cells. Cells were transfected with siRNA to knockdown AP-4, or were mock transfected (without siRNA) as a control. See also Supplementary Fig. 4. (a) Confocal microscopy with Airyscanning was used to image SERINC1-Clover (via anti-GFP) and ATG9A. Representative images show a confocal slice of the whole cell, and a peripheral 10x10 μm square imaged with Airyscanning in Superresolution mode, used for the quantification of colocalisation between SERINC1-Clover and ATG9A. Scale bar: 10 μm. (b) Quantification of colocalisation between SERINC1-Clover and ATG9A in peripheral regions of mock treated and AP-4 knockdown cells, using Thresholded Pearson’s Correlation Coefficient. 20 cells were quantified per condition. Data show mean ± SEM, and results of an unpaired two-tailed t-test: *** p ≤ 0.001. (c) Confocal microscopy with Airyscanning was used to image SERINC3-Clover (via anti-GFP) and anti-ATG9A, as in a. (d) Quantification of colocalisation between SERINC3-Clover and ATG9A in peripheral regions of mock treated and AP-4 knockdown cells, using Thresholded Pearson’s Correlation Coefficient. 19 cells were quantified per condition. Data show mean ± SEM, and results of an unpaired two-tailed t-test: *** p ≤ 0.001.

**Figure 5. ATG9A- and SERINC-positive puncta accumulate at the cell periphery in RUSC2-overexpressing cells.** (a) Widefield imaging of HeLa cells stably expressing GFP-RUSC2, mixed on coverslips with parental HeLa cells (marked with asterisks), labelled for ATG9A. The insets show accumulation of GFP-RUSC2- and ATG9A-positive puncta at the periphery of the cell. Scale bar: 20 μm. (b) Widefield imaging of HeLa cells expressing endogenously tagged SERINC1-Clover or SERINC3-Clover, transiently transfected with HA-RUSC2 and
double labelled with anti-GFP and anti-HA. Non-transfected cells are marked with asterisks. The insets show accumulation of HA-RUSC2- and SERINC-positive puncta at the periphery of the cell. Scale bars: 20 μm. See also Supplementary Fig. 5.

**Figure 6. RUSC2-driven accumulation of ATG9A-vesicles at the cell periphery depends on AP-4 and microtubules.** (a) Widefield imaging of AP4B1 knockout (KO) HeLa cells stably expressing GFP-RUSC2, labelled with anti-ATG9A, with or without rescue by transient expression of AP4B1. Scale bar: 20 μm. See also Supplementary Fig. 6. (b) Western blots of immunoprecipitates of GFP-RUSC2 from extracts of wild-type or AP4B1 KO HeLa cells stably expressing GFP-RUSC2. Parental wild-type HeLa as negative control. (c) Correlative light and electron microscopy (CLEM) of HeLa cells stably expressing GFP-RUSC2. The peripheral GFP-RUSC2 puncta corresponded to accumulations of small uncoated vesicular and tubular structures (EM areas A and B), which were not found in peripheral regions negative for GFP-RUSC2 (area C). Scale bars: fluorescence, 10 μm; EM, 500 nm. (d) Widefield imaging of HeLa cells stably expressing GFP-RUSC2, cultured with or without nocodazole (10 μg/ml, 2 hours), labelled with anti-ATG9A. Insets show how disruption of microtubules with nocodazole resulted in loss of the peripheral localisation of GFP-RUSC2 puncta, but their colocalisation with ATG9A remained.

**Figure 7. AP-4 knockout (KO) HeLa cells have elevated LC3B levels and enlarged autophagosomes.** (a) Western blots of whole-cell lysates from wild-type and AP4E1 KO HeLa cells, cultured in full medium or starved for one or two hours in EBSS, with or without the addition of bafilomycin A1 (100 nM, 2 hours); Clathrin heavy chain, loading control. (b) Western blots of whole-cell lysates from AP4B1 KO and AP4B1 KO HeLa cells rescued
with stable expression of AP4B1, as described in a. (c) Widefield imaging of wild-type, AP4B1 KO, and AP4B1 KO HeLa cells rescued with stable expression of AP4B1, starved for 2 hours in EBSS, labelled with anti-LC3B. Scale bar: 20 µm. (d) Quantification of the apparent size (in µm²) of LC3B puncta using an automated microscope. The experiment was performed in biological triplicate (mean indicated), and over 500 cells were scored per cell line in each replicate. Data were subjected to one-way ANOVA with Dunnett’s Multiple Comparison Test for significant differences to the wild-type: ** p ≤ 0.01; ns p > 0.05. See also Supplementary Fig. 7.

Figure 8. ATG9A mislocalisation is a ubiquitous phenotype in cells from AP-4-deficient patients. (a) Widefield imaging of fibroblasts from a healthy control individual, patients with homozygous mutations in one of the four AP-4 genes, and an individual with a heterozygous mutation in AP4E1 (phenotypically normal mother of the AP4E1 patient), labelled with anti-ATG9A and anti-TGN46. In the merged image, DAPI labelling of the nucleus is also shown (blue). Scale bar: 20 µm. (b) Western blots of whole cell lysates from the cells shown in a; Clathrin heavy chain, loading control. (c) Proposed model of AP-4-dependent trafficking. (1) AP-4 and its accessory proteins, TEPSIN, RUSC1 and RUSC2, are recruited to the TGN membrane where they concentrate their transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3, into a vesicle bud; (2) A vesicle carrying ATG9A and SERINCs, coated by AP-4 and its accessory proteins, buds from the TGN membrane; (3) AP-4 and TEPSIN fall off the vesicle membrane and are available for further rounds of vesicle budding at the TGN, while RUSCs remain associated with the vesicle; (4) The vesicle associates with microtubule transport machinery, via the RUSCs, for plus-end-directed transport to the cell periphery. AP-4 deficiency disrupts correct sorting and transport of ATG9A and SERINCs, and thus likely
interferes with their function. Cells with extreme geometry, such as neurons, may be particularly susceptible to such defects.
Supplementary Figure 1. Characterisation of AP-4 knockout (KO) HeLa cells. (a) Multiple sequence alignment of wild-type AP4E1 exon 6 and the mutant sequences recovered from AP4E1 KO clone x6C3. Allele 1 (34 bp deletion) was recovered seven times, allele 2 (28 bp deletion) six times and allele 3 (compound 53 bp deletion) four times. The alignment shows only the area of exon 6 surrounding the mutations (the remainder of the exon 6 sequence was identical in the mutants and the wild-type). The nucleotides are numbered based on the wild-type allele, starting from 1 for the first nucleotide of exon 6. All mutant alleles result in frameshift and the introduction of a premature termination codon in exon 6. Sequencing data for the AP4B1 KO clone were published previously26. (b) Widefield immunofluorescence imaging of AP4E1 and TEPSIN in wild-type and AP-4 KO HeLa cells. Note that the AP4E1 antibody has some background staining; the signal that is specific to AP4E1 is the cluster of puncta in the perinuclear region of the cell. AP-4 KO resulted in the concomitant loss of TEPSIN puncta from this region, indicative of loss of AP-4 function. Scale bar: 20 μm. (c) Global proteome analysis of AP-4 KO HeLa cells. Whole cell lysates from AP4B1 and AP4E1 KO HeLa cells were analysed by SILAC-based quantitative mass spectrometry, in comparison to lysates from heavy SILAC-labelled wild-type cells (in triplicate for each KO line). >6,500 proteins were quantified. Data were analysed with a two-tailed one sample t-test. Significance cut-offs were defined as $p \leq 0.02$ and a minimum absolute fold change ($\log_2$) of 0.45 (proteins marked with black or coloured circles meet these criteria, except ATG9A), with an estimated FDR of 25%. See also Supplementary Table 4.
Supplementary Figure 2. Orthogonal proteomic approaches to identify AP-4 cargo and accessory proteins. (a) SILAC quantitative proteomic profiling of AP-4-depleted vesicle fractions, with AP-4 depletion by knockdown (three replicates), 60 minutes knocksideways (two replicates), or knockout of AP4B1 or AP4E1 (two replicates each). This figure shows the nine individual experiments that were combined in Fig. 2b. SILAC ratios (wild-type/AP-4-depleted) from replicate experiments are plotted against each other. Proteins that are lost from the vesicle-enriched fraction in the absence of AP-4 are found in the top right sectors of the plots. The different depletion approaches act on different time scales, and hence have subtly different effects on vesicle composition. All methods show very similar overall trends though. (b-d) BioID with AP4B1 (b), AP4M1 (c) and AP4S1 (d) subunits. Comparison of protein abundance in affinity purifications of biotinylated proteins from HeLa cells stably expressing BirA*-tagged AP-4 subunits and control cell lines (HeLa, HeLa BirA* and HeLa GFP-BirA), analysed by label-free quantitative mass spectrometry (MS). Each experiment was performed in triplicate and the control dataset was compressed to the three highest LFQ intensities per protein (i.e. high stringency). Data were analysed with a two-tailed t-test: volcano lines indicate the significance threshold (FDR=5%). BioID is a proximity-based method, so different results were expected for the different AP-4 subunits. (e) Co-immunoprecipitation of AP-4 complexes via anti-GFP from HeLa cells stably expressing TEPSIN-GFP, using conventional immunoprecipitation conditions. The experiment was performed in duplicate and proteins were quantified by SILAC-based MS, relative to mock immunoprecipitations from parental HeLa controls. Proteins that co-purify with TEPSIN-GFP are: the four AP-4 subunits, heat shock proteins, HOOK1 (Protein Hook homolog 1), and FAM160A2 (FTS and Hook-interacting protein). HOOK1 and FAM160A2 are two members of
the FHF complex and FAM160A2 was previously identified in an affinity purification of the AP-4 complex. See also Supplementary Tables 3-5.

**Supplementary Figure 3. ATG9A accumulates at the trans-Golgi network in AP4E1 knockout Hela cells.** Widefield imaging of anti-ATG9A and anti-TGN46 in wild-type and *AP4E1* knockout HeLa cells. Scale bar: 20 μm.

**Supplementary Figure 4. Endogenously tagged SERINC1- and SERINC3-Clover are mistrafficked in AP-4-depleted HeLa cells.** (a) Vesicle-enriched fractions were prepared from HeLa SERINC1-Clover and HeLa SERINC3-Clover cells, with and without knockdown of AP-4 by siRNA. Western blots of input material and vesicle-enriched fractions; Clathrin heavy chain, loading control. As expected, SERINC1- and SERINC3-Clover were depleted from the vesicle-enriched fractions prepared from AP-4 knockdown cells, indicating that the tagged SERINCs are trafficked like the endogenous proteins. (b) Western blots of whole cell lysates from HeLa SERINC1- and SERINC3-Clover cells either mock transfected or transfected with siRNA to knock down AP-4, prepared in parallel to the cells used for imaging in the experiments shown in Fig. 4; Clathrin heavy chain, loading control. Note the AP4B1 antibody labels a non-specific band which is marked by the asterisk. (c) Confocal imaging of anti-GFP and anti-TGN46 in HeLa SERINC1-Clover cells, with or without AP-4 knockdown (control was mock transfected without siRNA). Scale bar: 10 μm. (d) HeLa SERINC3-Clover cells analysed as in c. SERINCs accumulate in the perinuclear region of AP-4-depleted cells, but do not show obvious overlap with TGN46.
**Supplementary Figure 5. Overexpression of RUSC2 results in accumulation of AP-4 cargo proteins at the periphery of the cell.** (a) Widefield imaging of HeLa cells stably expressing RUSC2-GFP, mixed on coverslips with parental HeLa cells (marked with asterisks), labelled with anti-ATG9A. The insets show accumulation of RUSC2-GFP- and ATG9A-positive puncta at the periphery of the cell. Scale bar: 20 µm. (b) Widefield imaging of a mixed population of HeLa cells stably expressing GFP-RUSC2 and HA-tagged SERINC3, labelled with anti-HA. Cells only positive for HA tagged SERINC3 are marked by an asterisk. The insets show accumulation of GFP-RUSC2- and HA-positive puncta at the periphery of the cell. Scale bar: 20 µm. (c) Widefield imaging of HeLa cells stably expressing GFP-RUSC2, mixed on coverslips with parental HeLa cells (marked with asterisks), labelled with anti-TGN46, anti-LAMP1, anti-EEA1 or anti-CIMPR. The insets show accumulation of GFP-RUSC2-positive puncta at the periphery of the cells, without redistribution of the co-labelled protein, demonstrating that the effect of RUSC2 overexpression is specific for AP-4 cargo proteins. Scale bar: 20 µm.

**Supplementary Figure 6. The effect of RUSC2 overexpression on the localisation of ATG9A is AP-4-dependent.** (a) Widefield imaging of HeLa cells stably expressing GFP-RUSC2 (marked with asterisks), mixed on coverslips with parental HeLa cells, labelled with anti-AP4E1. Overexpression of RUSC2 does not alter the distribution of AP-4 itself. Scale bar: 20 µm. (b) Widefield imaging of AP4E1 knockout HeLa cells stably expressing GFP-RUSC2, labelled with anti-ATG9A. GFP-RUSC2 puncta do not accumulate at the cell periphery, nor do they colocalise with ATG9A. Scale bar: 20 µm. (c) Widefield imaging of HeLa cells stably expressing GFP-RUSC2 treated with siRNA to knock down AP-4, labelled with anti-ATG9A. As above, GFP-RUSC2 puncta neither accumulate at the cell periphery, nor colocalise with ATG9A. Scale bar: 20 µm.

Davies et al., 2017
Supplementary Figure 7. AP-4 knockout HeLa cells have enlarged autophagosomes. Wild-type, AP4E1 knockout, AP4B1 knockout, and AP4B1 knockout HeLa cells rescued with stable expression of AP4B1 were starved for two hours in EBSS and then fixed and labelled with anti-LC3B. LC3B puncta were quantified using an automated microscope (data from the same experiment as that shown in Fig. 7d). The experiment was performed in biological triplicate (mean indicated) and more than 500 cells were scored per cell line in each repeat. Data were analysed by one-way ANOVA with Dunnett’s Multiple Comparison Test for significant differences to the wild-type: ns p > 0.05; *** p ≤ 0.001. (a) Quantification of the total number of LC3B-positive spots per cell in each cell line showed no significant difference between the cell lines. (b) Quantification of the apparent size (in μm²) of LC3B puncta in wild-type and AP4E1 knockout cells. The average spot area (in μm²) was significantly larger in the AP4E1 knockout cells, as was observed for the AP4B1 knockout line (Fig. 7d).
Supplementary Tables

Supplementary Table 1: Dynamic Organellar Maps profiles and MR plot shift analysis.

Supplementary Table 2: Dynamic Organellar Maps marker protein neighbourhood analysis.

Supplementary Table 3: AP-4 vesicle profiling MS data.

Supplementary Table 4: AP-4 knockouts proteomic analyses and TEPSIN-GFP IP MS data.

Supplementary Table 5: AP-4 BioID MS data.
Figure 1 Davies et al. 2017
Figure 2 Davies et al. 2017

Figure 2a: Schematic diagram illustrating the SILAC ratios for 2848 proteins across 9 experiments.

Figure 2b: PCA plot comparing control and AP-4-depleted vesicle fractions.

Figure 2c: Illustration of RUSC1 and RUSC2 proteins with their respective domains.

Figure 2d: Scatter plot showing the -Log_{10} p value against Log_{2} fold difference in abundance for AP-4 knockouts vs. wild-type.

Figure 2e: Scatter plot showing the -Log_{10} p value against Log_{2} fold difference in abundance for AP4E1-BirA* vs. BioID controls.

Figure 2f: Scatter plot showing Log_{2} fold enrichment in IP 2 against Log_{2} fold enrichment in IP 1 for Sensitive TEPSIN-GFP IP.

Figure 2g: Table summarizing the GST pulldowns results.

Figure 2h: Bar graph showing estimated copy number (x1000) per cell for different proteins.
Figure 3 Davies et al. 2017

(a) Wild-type, ATG9A TGN46 Merge

(b) Relative ATG9A overlap with TGN46

(c) Control AP4B1 knockout AP4E1 knockout

(d) ATG9A TGN46 Merge

Figure 3 Davies et al. 2017
Figure 4 Davies et al. 2017
**Figure 7** Davies et al. 2017

(a) **Wild-type vs. AP4E1 knockout**

|                | Non-starved | 1 hour starved | 2 hours starved |
|----------------|-------------|----------------|-----------------|
| Baf A1:        | -           | +              | +               |
| AP4E1:         | +           | +              | +               |

kDa

- 15
- 130
- 100
- 70
- 250

(b) **Rescue vs. AP4B1 knockout**

|                | Non-starved | 1 hour starved | 2 hours starved |
|----------------|-------------|----------------|-----------------|
| Baf A1:        | -           | -              | +               |
| AP4B1:         | +           | +              | +               |

kDa

- 15
- 130
- 100
- 70
- 250

(c) **LC3B**

1. Wild-type
2. AP4B1 KO
3. Rescue

(d) **Mean spot avg. area (μm²)**

- WT
- KO
- Rescue

**ns**

**Figure 7** Davies et al. 2017
Figure 8 Davies et al. 2017

**Figure a**
- ATG9A, TGN46, and Merge images for Control, AP4B1, AP4E1, AP4M1, AP4S1, AP4E1 Het conditions.

**Figure b**
- Western blot analysis showing protein expression levels for Control and AP-4 deficient patient cells.
- Proteins: AP4E1, AP4B1, ATG9A, and Clathrin.

**Figure c**
- Diagram illustrating the steps of cargo trafficking from TGN to Microtubule.
- Steps: 1. AP-4 binding, 2. TEPSIN/RUSC1/2 recruitment, 3. Assembly ofvesicles, 4. Cargo delivery.
- Proteins: AP-4, TEPSIN, RUSC1/2, ATG9A, SERINC1/3, Kinesin.
**a**

Supplementary Figure 1 Davies et al. 2017

Wild-type:  
AP4E1 KO_1:  
AP4E1 KO_2:  
AP4E1 KO_3:  

AP4E1 TEPSIN Merge

**b**

[Images of cellular staining showing wild-type and AP4E1 knockout conditions with merged images of AP4E1 and TEPSIN, and a merge column.]

**c**

Whole cell lysates

Depleted in KOs

Enriched in KOs

-Log$_{10}$ p value vs. Log$_{2}$ fold difference in abundance

AP-4 knockouts vs. wild-type

- **ATG9A**
- **SERINC1**
- **MAP1LC3B**
- **RUSC1**
- **GABARAPL2**
- **AP4E1**
- **AP4M10**
- **SERINC3**

Supplementary Figure 1 Davies et al. 2017
Supplementary Figure 3 Davies et al. 2017

Wild-type

AP4E1 knockout
